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1. Introduction 
1.1. Cardiac disease - an overview 
Cardiac disease or cardiopathy is a broad term for a variety of diseases affecting the heart. 
In modern times, cardiac disease has emerged as the leading cause of death worldwide, 
particularly in developed countries. According to the World Health Organization (WHO), 
16.7 million deaths worldwide in 2003 (29.2% of total global deaths) were caused by 
some form of cardiovascular disease. Though the rate of cardiac disease is highest in 
developed countries, developing countries are also seeing an increase in occurrence of 
cardiac diseases, as well as corresponding rise in the number of heart-related deaths 
(Ahrens I et al., 2010). The WHO estimates that by 2010, cardiac disease will surpass 
Acquired immune deficiency syndrome (AIDS) as the leading cause of death in 
developing countries (WHO 2006). 
The resulting costs of cardiac disease are diverse, starting from the cost to individual and 
his family of health care and time off work, the cost to the government of health care, and 
finally the cost to the country owing to lost productivity. According to the American 
Heart Association, the cost of cardiovascular diseases and stroke in the United States was 
estimated to be $503.2 billion in 2010, which is higher than for any other diagnostic group 
(Lloyd-Jones D et al., 2010). This included both the direct and indirect costs. The direct 
costs included the cost of physicians and other health professionals, hospital and nursing 
home services, the cost of medications, home health care and other medical durables. 
Indirect costs include lost productivity that results from illness and death. This is only the 
economic cost. The true cost in human terms of suffering and lost lives is incalculable. 
1.1.1. Heart failure– a rising global burden 
Heart failure (HF) is generally defined as inability of the heart to supply sufficient blood 
flow to meet the body’s need. The common causes of HF include myocardial infarction 
(heart attack) and other forms of ischemic heart disease, hypertension, valvular heart 
disease, and cardiomyopathy (McMurray and Pfeffer, 2005). 
HF is a common, costly, disabling, and potentially deadly condition. In developed 
countries, around 2% of adults suffer from HF, but in those over the age of 65, this 
increases to 6-10% (McMurray and Pfeffer, 2005; Dickstein K et al., 2008). It is 
associated with high health expenditure mostly due to hospitalization costs. In the United 
Kingdom, these costs account for almost 2% of the total budget of the National Health 
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Service, while in the United States it amounts to more than $35 billion (Stewart S et al., 
2002; Rosamond W et al., 2008). HF is associated with significantly reduced physical and 
mental health, resulting in a marked decrease in quality of life (Juenger J et al., 2002; 
Hobbs FD et al., 2002). With the exception of HF caused by reversible causes, the 
condition usually worsens with time. Although some people survive many years, 
progressive disease is associated with an overall annual mortality rate of 10% (Neubauer 
S, 2007). It is the leading cause of hospitalization in people older than 65 years 
(Krumholz HM et al., 2000). HF affects approximately 5 million people in the United 
States, and each year close to 500,000 new cases are diagnosed. The number of deaths in 
the United States from this condition has more than doubled since 1979, averaging 
250,000 annually (Allman E et al., 2009). 
1.1.2. What is dilated cardiomyopathy? 
Cardiomyopathy which literally means “heart muscle disease” is the impairment of 
function of the myocardium (i.e. the actual heart muscle), due to any reason. In practice, 
this term is reserved for severe myocardial disease leading to HF. People with 
cardiomyopathy are often at risk of arrhythmia or sudden cardiac death or both (Kasper 
DL et al., 2005). 
Dilated cardiomyopathy (DCM) is a type of cardiomyopathy in which heart muscle 
becomes weakened and enlarged, and cannot pump blood efficiently anymore. The 
decrease in heart function can affect the lungs, brain, liver and other body systems. In 
DCM, a portion of the myocardium is dilated, often without any obvious cause. Left or 
right ventricular systolic pump function of the heart is impaired, leading to progressive 
cardiac enlargement and hypertrophy by the process of remodeling. 
DCM is the most common form of non-ischemic cardiomyopathy. It occurs more 
frequently in men than in women, and is most common between the ages of 20 and 60 
years. About one in three cases of congestive heart failure is due to dilated 
cardiomyopathy (Robbins SL et al., 2003; Kasper DL et al., 2005). 
Although in many cases no cause (etiology) is apparent, DCM is probably the result of 
damage to myocardium produced by a variety of toxic, metabolic, or infectious agents. It 
may be due to a fibrous change of the myocardium resulting from a previous myocardial 
infarction. Acute viral myocarditis such as with coxsackievirus B and other enteroviruses, 
may also present with DCM as a late sequel, possibly being mediated via an 
immunological mechanism (Martino TA et al., 1994). Autoimmune mechanisms are also 
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suggested as a cause for DCM (San Martin MA et al., 2002). However, many cases of 
DCM are described as idiopathic - meaning that the cause is unknown. 
1.1.3. Chagas’ disease 
1.1.3.1. Background of Chagas’ disease 
Chagas’ disease (CD) (also known as American trypanosomiasis) is a parasitic disease 
caused by the hemoflagellate protozoan, Trypanosoma cruzi (T.cruzi). It is found mainly 
in Central and South America, where it is transmitted to humans and other mammals 
mostly by an insect vector, the blood sucking bugs of the subfamily Triatominae (family 
Reduviidae). Nearly 10 million people are infected worldwide, and more than 25 million 
people are at risk of the disease (Chagas disease [American trypanosomiasis] fact sheet 
[revised in June 2010]). 
Findings from paleoparasitology studies on T.cruzi DNA recovered from human mummies 
have revealed that CD afflicted man as early as 9000 years ago (Aufderheidi AC et al., 
2004). However, it was not until 1909 when a Brazilian physician, Carlos Chagas (1879-
1934) described the disease for the first time, which was later named after him. Chagas’ 
work is unique in history of medicine because he was the only researcher so far to 
describe solely and completely a new infectious disease: its pathogen, vector, host, 
clinical manifestations, and epidemiology. Infact, the first reported case of CD might have 
preceded Carlos Chagas’ discovery- Charles Darwin quite possibly contracted T.cruzi 
infection during his expedition to South America in 1835, as suggested by his vivid 
description of contact with the kissing bug, triatomine, and by some of his symptoms in 
later life (Bernstein RE, 1984). 
1.1.3.2. Pathogenesis of Chagas’ disease 
In acute phase of T.cruzi infection, organ and tissue damage is caused by the parasite 
itself and by the acute inflammatory response of the host, which is induced by the 
presence of the parasite (Andrade ZA, 1999). There is a strong T-helper-1 immune 
response with presence of both CD4 and CD8 cells, and characterized by the production 
of certain cytokines like tumour necrosis factor alpha (TNF alpha), interferon gamma, and 
interleukin 12 (IL-12), that are important in the control of parasitism (Abrahamsohn IA 
and Coffman RL, 1996; Silva JS et al., 1998; Martins GA et al., 1999). These cytokines 
cause the activation of trypanocidal activity of human macrophages mainly via a nitric 
oxide (NO)-dependent mechanism (Chandra M et al., 2002; Gutierrez FR et al., 2009). In 
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comparison, production of cytokines like IL-10 and transforming growth factor beta (TGF 
beta) lead to increased replication and resistance of the parasite due to inhibition of 
macrophage trypanocidal activity (Silva JS et al., 1991; Reed SG et al., 1994). Overall the 
T-helper-1 immune response has a protective role against T.cruzi infection mainly 
through the synthesis of nitric oxide that exerts a potent trypanocidal action. 
During chronic infection, the balance between immune mediated parasitic control and 
inflammatory damage to host tissues probably determines the course of disease. In case, 
the immunological response is inefficient and causes tissue damage, the parasite load will 
increase and further exacerbate the immune-mediated inflammation. In contrast, a well 
mediated immune response will not only lead to effective parasitic control, but also 
minimize the damaging effects of inflammation on host tissues (Tarleton RL, 2003). 
Although the pathogenesis of chronic CD is not well understood, there is a growing 
consensus that the persistence of parasite inside the host tissue is necessary for 
development of disease (Kierszenbaum F, 2007; Bonney KM and Engman DM, 2008). 
However, it is still unclear whether tissue damage mostly occurs due to direct parasite 
factors, or is indirectly caused by parasite-induced immunopathological or auto-immune 
mechanisms (Soares MB et al., 2001; Marin-Neto JA et al., 2007). 
In chronic CD patients with cardiomyopathy, there is low intensity but slowly 
progressive, persistent myocarditis that leads to gradual impairment of contractile 
function and dilation of all four chambers of the heart. Left ventricular apical aneurysms, 
thromboembolic disease and other segmental wall motion abnormalities are common in 
the relatively early stages of the disease (Acquatella H, 2007). Histological examination 
reveals widespread destruction of myocardial cells, edema, diffuse fibrosis, mononuclear 
cellular infiltration of the myocardium and scarring of the conduction system (Andrade 
ZA, 1983). All these changes are responsible for the frequent pathological occurrences of 
atrio-ventricular blocks, inter-ventricular blocks, and sinus nodal rhythm dysfunction in 
CD. Progressive loss of myocardial fibers and the replacement of dead myocytes by 
intense fibrosis predispose the patient to development of HF and ventricular arrhythmias 
(Rassi A Jr et al., 2000; Rassi A Jr et al., 2009). In addition, pathological changes in 
coronary microvasculature may further exacerbate the myocardial damage (Rossi MA, 
1990; Marin-Neto JA et al., 1992). 
Chronic Chagas’ gastrointestinal disease is caused by destruction of intramural autonomic 
ganglia, predominantly in the esophagus, colon or both. This leads to loss of peristaltic 
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movements in the affected sections of the gastrointestinal tract, thus causing mega disease 
(megaesophagus and/or megacolon) (Kőberle F, 1968). 
1.1.3.3. Clinical manifestations of Chagas’ disease 
Human exposure to T.cruzi may lead to an acute Chagas’ infection, which usually lasts 
for 4-8 weeks. The chronic phase that follows persists for lifespan of the host (WHO, 
2002; Rassi A Jr et al., 2010). Acute phase is in most cases asymptomatic, but sometimes 
it may present as a self-limiting febrile illness. Symptoms usually occur 1-2 weeks after 
exposure to the infected triatomine bugs, or up to a few months after infected blood 
transfusion. Treatment with anti-parasitic drugs like benznidazole cures most cases of 
acute infection (Pinto AY et al., 2009), and prevents any chronic manifestations. 
However, death can occasionally occur in acute phase (<5-10% of symptomatic cases) 
due to severe myocarditis or meningoencephalitis, or both. 
Symptoms of acute phase subside spontaneously in about 90% of patients even without 
initiating anti-trypanosomal treatment. Almost 60-70% of infected individuals will then 
enter an asymptomatic phase, where they will never develop any clinically apparent 
disease. Such patients have the indeterminate form of chronic CD, which is characterized 
by positivity for anti-T.cruzi antibodies in patient’s serum, a normal 12-lead 
electrocardiogram (ECG), and normal radiological scans of the chest, esophagus, and 
colon. The remaining 30-40% of cases will develop a determinate (clinical) form of 
chronic CD, usually 10-30 years after the initial infection (Pinto Dias JC, 1995). The 
clinical manifestations may be in the form of cardiac, digestive (megaesophagus and 
megacolon), or cardiodigestive diseases. A direct progression from acute phase to a 
clinical form of CD may occur in few patients (5-10%). Reactivation of CD is also 
possible in chronically infected patients who develop an immunocompromised condition 
due to immunosuppressive drug therapy, or co-infection with human immunodeficiency 
virus (HIV) (LM Braz et al., 2008). 
1.1.3.3.1. Acute Phase 
The acute phase of CD is mostly asymptomatic, which is probably due to the low parasite 
load. When present, symptoms usually include fever, headache, malaise, and mild 
enlargement of spleen, liver, and lymph nodes. There may be clinical findings at the site 
of inoculation of T.cruzi, either in the eye_ Romaña sign (unilateral eyelid edema, 
conjunctivitis, and lymphadenopathy), or on the skin_ a chagoma (firm, dusky red 
swelling with localized lymphadenopathy). An ECG might reveal sinus tachycardia, low 
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QRS voltage, first-degree atrioventricular block, or primary T-wave changes. There may 
also be variable degrees of cardiomegaly visible on a chest radiograph (Rassi A Jr et al., 
2000; WHO 2002). 
In congenitally infected infants, symptoms usually appear at birth or few weeks after 
delivery. Common symptoms include fever, hypotonicity, hepatosplenomegaly, and 
anemia. There may be findings of prematurity and low birth-weight (Bittencourt AL, 
1976; Freilij H and Altcheh J, 1995). In-utero infections can also lead to placentitis and 
abortion. Serious manifestations like meningoencephalitis and myocarditis are rare in CD 
patients, but when present, they have high risk of mortality (Torrico F et al., 2004). 
1.1.3.3.2. Chronic Phase 
The typical clinical manifestations of chronic phase are related to pathological 
involvement of heart, esophagus, colon, or a combination, and are grouped into three 
major forms: cardiac, digestive, and cardio-digestive (Marin Neto JA et al., 1999). 
The digestive form is seen mainly in regions south of the Amazon basin (Argentina, 
Brazil, Chile, and Bolivia). This geographical distribution is most likely due to differences 
in parasite strains (Miles MA et al., 2003). Gastrointestinal dysfunction (megaesophagus 
and/or megacolon) arises in 10-15% of chronically infected patients. The 
megaoesophagus can lead to dysphagia (difficulty in swallowing) and odynophagia (pain 
during swallowing), together with epigastric pain, regurgitation, and malnutrition in 
severe cases. There is also an increased risk of cancer of the esophagus in CD patients 
with megaesophagus. Megacolon, which commonly affects the sigmoid colon and rectum, 
leads to severe constipation, abdominal distension and pain, and occasionally results in a 
large bowel obstruction due to fecaloma or sigmoid volvulus (Brandalise NA et al., 
1985). 
The cardiac form is the most frequent and serious manifestation of chronic CD. It 
develops in 20-30% of individuals and usually leads to abnormalities of the conduction 
system, tachyarrhythmias and bradyarrhythmias, apical aneurysms, thromboembolism, 
heart failure, and sudden death (Marin Neto JA et al., 1999; Rassi A Jr et al., 2000). 
Common ECG abnormalities include right bundle branch block, left anterior fascicular 
block, abnormal Q waves, premature (ectopic) ventricular beats, and low voltage of QRS 
complex. Episodes of non-sustained ventricular tachycardia are observed in 40% of 
patients with mild abnormalities of wall motion, and in almost all patients with HF, which 
is more common than in other cardiomyopathies (Rassi A Jr et al., 1995). 
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HF is often a late manifestation of CD. It is mostly biventricular with a predominance of 
right-sided failure (peripheral edema, ascites, and hepatomegaly are more prominent than 
pulmonary congestion) at advanced stages. Isolated left-sided HF can be present in the 
early stages of cardiac decompensation. HF due to CD is associated with higher mortality 
than is HF from other causes (Freitas HF et al., 2005). 
Systemic and pulmonary embolisms arising from mural thrombi in the cardiac chambers 
are quite common, especially in the brain, lungs, and limbs (Oliveira JSM et al., 1983). 
As a result, CD is an independent risk factor for stroke in endemic countries (Carod-Artal 
FJ et al., 2005). 
Sudden death is the major cause of death in patients with cardiomyopathy due to CD. It 
accounts for almost two-thirds of all deaths, followed by refractory HF (25-30%), and 
thromboembolism (10-15%) (Rassi A Jr. et al., 2001). Sudden cardiac death can also 
occur in patients who were previously asymptomatic. It is commonly associated with 
ventricular tachycardia and fibrillation or, less likely, with sinus node dysfunction or 
complete atrioventricular block. The leading causes of death vary depending on the stage 
of the disease, with sudden death being predominant at early stage, and death from HF 
being more common at advanced stages. 
There might be an exacerbation of chronic infection in patients with AIDS or those 
receiving immunosuppressive therapy, which can lead to increases in parasitemia and 
replication of intracellular parasite. Fever, skin lesions, myocarditis, and panniculitis are 
common in recipients of solid organs or bone marrow transplants (Altclas J et al., 2005; 
Fiorelli AI et al., 2005), whereas meningoencephalitis and myocarditis are more 
commonly seen in patients with AIDS (Vaidian AK et al., 2004; Sartori AM et al., 2007). 
1.1.3.4. Epidemiology of Chagas’ disease 
CD is endemic throughout most of South and Central America, including some southern 
regions of United States especially the state of Texas (Hotez PJ, 2014). Originally it was 
confined to the poor, rural areas of Latin America, in which vector-borne transmission to 
man occurs (Moncayo A, 2003). 
In countrywide surveys in 1980s, nearly 17.4 million people were estimated to be 
infected, and 100 million (i.e. 25% of all inhabitants of Latin America) were at risk of 
infection in 18 endemic countries in 1980-85 (WHO 2002). According to the Pan 
American Health Organization, 20% of population of Latin America were at risk (109 
million individuals) and approximately 7.7 million individuals were infected in 2005 
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(Aguilar VHM et al., 1999). In a recent Chagas’ disease factsheet by WHO, it is estimated 
that 10 million people are infected worldwide, mostly in Latin America where CD is 
endemic, and more than 25 million people are at risk of the disease. It is estimated that in 
2008, CD killed more than 10,000 people (Chagas disease [American trypanosomiasis] 
fact sheet [revised in June 2010]). 
In the past few decades, improved programs for vector control and compulsory blood 
bank screening have significantly reduced new cases of infection and decreased the 
burden of CD in Latin America. The incidence of new cases of CD dropped from 700,000 
per year in 1990 to 41200 per year in 2006. Similarly, number of deaths from CD fell 
from 50,000 per year in 1990 to 12,500 per year in 2006 (Moncayo A and Silveira AC, 
2009). However, the recent influx of immigrants from countries endemic for disease has 
meant that CD is becoming a major health concern in USA and Canada and in many parts 
of Europe and the western Pacific, where an increasing number of infected individuals 
have been identified (Schmunis GA, 2007; Guerri-Guttenberg RA et al., 2008). The most 
common destination for migrants from Latin America is the USA, where an estimated 
300,167 individuals (mainly from Mexico) are infected with T.cruzi (Bern C and 
Montgomery SP, 2009). Spain has the second highest number of infected immigrants, 
with an estimated 47,738 - 67,423 individuals, most of them originating from Argentina, 
Ecuador, Bolivia and Peru (Gascon J et al., 2010). Other countries like France, Canada, 
Japan, and Australia have also reported cases of CD and are at increasing risk due to flow 
of migrants. 
1.1.3.5. Diagnosis of Chagas’ disease 
For diagnosis of an acute infection, microscopic examination of peripheral blood is done 
for detection of trypomastigotes (Gomes YM et al., 2009). Micro-hematocrit is the 
preferred method for diagnosis of congenital infections as it has a high sensitivity and 
only a small amount of blood is required. Microscopic examination of cord or peripheral 
blood by this method is highly recommended in neonates (Bittencourt AL, 1976; Freilij H 
and Altcheh J, 1995). In case results are repeatedly negative or test is not done early in 
life, then the infant should be tested for anti-T.cruzi IgG antibodies at 6-9 months of age 
when maternal antibodies are no longer present in infant’s serum. In specialized centers, 
PCR (polymerase chain reaction) techniques based upon amplification of T.cruzi DNA 
detection, can be used for early detection of congenital infections. This method tends to 
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have a higher sensitivity than microscopic examination (Mora MC et al., 2005; 
Russomando G et al., 2005; Diez CN et al., 2008). 
In cases of chronic infection, as the parasitemia is very low, direct microscopic 
examination of patient’s blood is no longer a reliable method. Instead the presence of IgG 
antibodies against T.cruzi antigens is detected by at least two different serological 
methods (usually enzyme linked immunosorbent assay, indirect immunofluorescence, or 
indirect haemagglutination) to confirm diagnosis (Gomes YM et al., 2009). PCR is not 
used in routine diagnosis because of the need for specific laboratory facilities, poor 
standardization, potential DNA cross-contamination, and variable results across 
laboratories and countries. However, due to its high sensitivity compared with other 
parasitological methods, PCR can be potentially used for confirmation of diagnosis in 
cases of inconclusive serology, and as an additional method to monitor treatment (Britto 
CC, 2009). It can be used to identify treatment failure from positive detection of T.cruzi 
DNA, but not for treatment success, since even repeated negative PCR results do not 
necessarily indicate complete cure. 
1.1.3.6. Treatment of Chagas’ disease 
1.1.3.6.1. Anti-trypanosomal treatment 
Anti-trypanosomal treatment is strongly recommended for all cases of acute, congenital, 
and reactivated infection, for all children with infection, and for patients up to 18 years of 
age with chronic disease. Drug treatment should be offered to adults aged 19-50 years 
without advanced CD, and is optional for those older than 50 years because benefit has 
not been proven in this group of population (Bern C et al., 2007). Anti-trypanosomal 
treatment is contraindicated during pregnancy and in patients with severe hepatic or renal 
insufficiency, and generally is not offered to patients with advanced CD or 
megaoesophagus with profound impairment of swallowing. 
Benznidazole and nifurtimox are the drugs of choice, having proven efficacy against CD 
(de Andrade AL et al., 1996; Sosa Estani S et al., 1998; Viotti R et al., 2006; Fabbro DL 
et al., 2007). Benznidazole has the best safety and efficacy profile (Viotti R et al., 2009), 
and is therefore usually used as first-line treatment. 
1.1.3.6.2. Treatment of cardiac symptoms 
Amiodarone can improve survival in patients with cardiomyopathy due to CD who are at 
high risk of death from malignant arrhythmias (Scanavacca MI et al., 1990; Rassi A Jr et 
al., 1995; Rassi A Jr et al., 2001). It is therefore commonly recommended as the treatment 
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of choice for all patients with sustained ventricular tachycardia and for those with non-
sustained ventricular tachycardia and myocardial dysfunction (Scanavacca MI et al., 
2002). 
Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers 
(ARBs) are the mainstay of treatment for CD patients with HF. Diuretics are also 
frequently used due to predominance of systemic congestive symptoms over signs of 
pulmonary congestion. However, ß blockers are not used as frequently as they are in HF 
from other causes. This is due to the reason that CD patients with cardiomyopathy also 
have profound conduction abnormalities and tend to have symptomatic bradycardia that 
can be exacerbated with the use of ß blockers (Quiros FR et al., 2006). 
Cardiac resynchronization is another form of treatment for HF and is mostly administered 
to patients with left bundle branch block. Cardiac transplantation is an effective 
alternative for patients with end stage HF (Bocchi EA and Fiorelli A, 2001). Due to the 
high occurrence of thromboembolic conditions, oral anticoagulants are recommended for 
patients with atrial fibrillation, previous embolism, and apical aneurysms with recent 
thrombi. 
1.1.3.6.3. Treatment of gastrointestinal symptoms 
Treatment of mega-esophagus is focused on palliation of symptoms by aiding the transit 
of food and liquids through the achalasic lower esophageal sphincter. Surgical techniques 
like laparoscopic Heller’s myotomy and fundoplication are used for treatment of non-
advanced mega-esophagus. In advanced cases, different techniques of esophageal 
resection are used (Herbella FA et al., 2008). 
The early stage of colonic dysfunction can be treated with a fiber-rich diet and abundant 
intake of fluids, together with laxatives and occasional enema. Fecal impaction can occur 
as the disease progresses requiring manual emptying under general anesthesia. Patients 
with megacolon who do not respond to conservative treatment and those with frequent 
fecaloma or sigmoid volvulus, need to undergo surgical organ resection (Garcia RL et al., 
2008). 
1.1.3.7. Economic burden of Chagas’ disease 
Regarded by WHO as one of the thirteen most neglected tropical diseases in the world 
(Hotez PJ et al., 2007), CD continues to be a major source of financial, social and health 
burden to the affected individuals and countries (Mathers CD et al., 2007). The economic 
impact of the disease especially during chronic phase is very high as it represents the most 
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common cause of cardiac lesions in the young, economically productive adults in endemic 
countries of Latin America (Moncayo A and Silveira AC, 2009). The early mortality and 
severe disability associated with CD results in huge financial losses every year in these 
developing countries. In Latin America, CD holds fourth place amongst infectious and 
parasitic diseases with the largest burden of the disease. It is associated with 0.7 million 
disability-adjusted life years (DALYs), just behind diarrheal diseases, HIV, and 
tuberculosis (Hotez PJ et al., 2006). 
Poor housing conditions, lack of screening at blood banks, inadequate prenatal and health 
care facilities have resulted in the persistence of CD in many areas of Latin America that 
are still developing. It has put a massive burden on poor families in rural areas, as the 
financial, social and health consequences of the disease only contribute towards 
maintaining the cycle of poverty. Furthermore, a huge load is also put on the health care 
system due to hospitalizations and medical and surgical treatments, especially as a 
consequence of chronic manifestations of disease like cardiomyopathy, gastrointestinal 
dysfunction, and meningo-encephalitis. The annual financial loss due to early morbidity 
and mortality from CD in Latin America is estimated to be as high as 18 billion dollars 
(Franco-Paredes C et al., 2007). 
1.1.3.8. Worldwide importance of Chagas’ disease 
Due to the recent advancements in communication and technology, it has become much 
easier to travel from one part of the world to another. However, globalization 
phenomenon has also enabled the spread of infectious diseases across countries and 
continents to regions where it previously did not exist, or had been eradicated only to see 
it re-emerge again. CD was originally confined to the rural areas, where poor housing 
conditions and inadequate health care facilities favour its existence. However, with the 
rising urbanization trend, where people are migrating to big cities for better opportunities, 
CD is now no longer limited to the endemic, rural areas of Latin America. A large number 
of people are also migrating from CD endemic countries to more developed countries, 
especially in North America (USA and Canada) and Europe. 
The spread of CD to non-endemic regions has largely been facilitated by the fact that CD 
is transmissible by blood transfusion and organ transplantation, and there are no specific 
tests at blood banks or hospitals to screen it. As a result, there are already several 
registered cases of infection via blood transfusion and organ transplantation in United 
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States and Europe (Centers for Disease Control and Prevention [CDC], 2006; Young C et 
al., 2007; Florez-Chavez M et al., 2008). 
Vertical transmission is another way of spreading the disease as children born with 
T.cruzi infection mostly remain undiagnosed, transmitting the disease later on in life via 
blood transfusion or organ donation, or in the case of women, giving birth to infected 
newborns, thus perpetuating the cycle of congenital transmission (Muñoz J et al., 2007). 
1.2. Biomarkers in cardiac diseases 
1.2.1. Introduction to biomarkers 
The accurate diagnosis and prevention of cardiac diseases is an important public health 
goal. Although clinical characteristics such as age and gender are well established risk 
factors for cardiac diseases, such features are not sufficient to identify all patients at risk. 
Cardiac biomarkers are one such tool to better identify high-risk individuals, to diagnose 
disease conditions promptly and accurately, and to effectively prognosticate and treat 
patients with disease. However, most current biomarkers have only modest predictive 
value, and there is a need to identify additional biomarkers from new biological pathways. 
A biomarker is actually defined as a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to therapeutic intervention (Biomarkers Definitions Working 
Group, 2001). It may be measured on a bio-sample (as a blood, urine, or tissue test), it 
may be a recording obtained from a person (blood pressure, ECG, or Holter), or it may be 
an imaging test (echocardiogram or CT scan). Accordingly, biomarkers can be classified 
as antecedent biomarkers (identifying the risk of developing an illness), screening 
biomarkers (screening for subclinical disease), diagnostic biomarkers (recognizing overt 
disease), staging biomarkers (categorizing disease severity),or prognostic biomarkers 
(predicting future disease course, including recurrence and response to therapy, and 
monitoring efficacy of therapy). 
The overall expectation of a cardiac disease biomarker is to enhance the ability of the 
clinician to optimally manage the patient. A new biomarker will be of clinical value only 
if it is accurate and is reproducibly obtained in a standardized fashion. It should be 
acceptable to the patient and easy to interpret by clinicians. In addition, it should have 
high sensitivity and high specificity for the outcome it is expected to identify (Fox N and 
Growdon JH, 2004). 
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1.2.2. Role of biomarkers in heart failure 
HF appears to result not only from cardiac overload or injury but also from a complex 
interaction among various genetic, neurohormonal, inflammatory, and biochemical factors 
that act on the cardiac myocytes and the interstitium. An increasing number of enzymes, 
hormones, biologic substances, and other markers of cardiac stress and injury are gaining 
clinical importance as biomarkers. These biomarkers provide important information 
regarding the identification of individuals at risk of HF, diagnosis of HF, risk stratification 
and in monitoring therapy, as well as about the pathogenesis of HF. Many biomarkers 
may be risk factors themselves and therefore potential targets of therapy. As inflammation 
is important in the pathogenesis and progression of many forms of HF, various 
inflammatory biomarkers have been identified that have proved useful in HF. These 
include C-reactive protein (CRP), TNF alpha, and interleukins1, 6, and 10 (Anker SD and 
von Haehling S, 2004). Neurohormonal disturbances also play a role in the pathogenesis 
of HF, including the activation of the renin-angiotensin-aldosterone system, and 
subsequent stimulation of sympathetic nervous system, leading to abnormally elevated 
levels of norepinephrine in plasma (Cohn JN et al., 1984; Swedberg K et al., 1990). Brain 
natriuretic peptide (BNP) is an important indicator of myocyte stress. It is formed by the 
myocytes during hemodynamic stress such as when the ventricles are dilated, 
hypertrophic, or subject to increased wall tension. BNP causes arterial vasodilation, 
diuresis, and natriuresis, and reduces the activities of the renin-angiotensin-aldosterone 
system and the sympathetic nervous system (Moreira Mda C et al., 2008). Thus, BNP acts 
to oppose the physiologic abnormalities in HF. It serves as a useful biomarker in the 
diagnosis and risk stratification of patients with chronic HF. Also, BNP together with 
atrial natriuretic peptide (ANP) are effective in screening of asymptomatic patients at risk 
of developing HF, such as the elderly and those with diabetes and hypertension. N-
terminal pro-BNP, due to its longer half-life, is more accurate as an indicator for 
ventricular stress and for prognosis (Masson S et al., 2006). However, BNP cannot be 
used as a biomarker for differentiating between CD and DCM due to other causes. 
Chagas’ serology and echocardiography must be performed additionally to differentiate 
between CD and DCM. 
1.2.3. Role of biomarkers in Chagas’ disease 
The clinical manifestations of CD are variable, but most of the individuals infected with 
T.cruzi remain asymptomatic for decades. Therefore, transmission of CD via blood 
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transfusion and organ transplantation still occurs in countries where CD is endemic and in 
those where it is not. Vertical transmission is also a possibility as CD can pass 
unsuspected from mother to child for several generations. All the current diagnostic and 
screening tests have limitations. Therefore, new approaches are needed for blood bank 
screening as well as for improved diagnosis and prognosis. There is no gold standard 
assay for CD, but tests currently in use include enzyme- linked immunosorbent assay 
(ELISA), PCR, indirect immunofluorescence assay (IFA), and xenodiagnosis. Although 
serologic screening tests have greatly reduced the risk of transmission of CD, these 
methods are still imperfect and better tests are needed to protect transfusion and transplant 
recipients worldwide. In recent times, there have been various studies to identify useful 
biomarkers for early screening and diagnosis of CD. A new ELISA technique, the Ortho 
T.cruzi ELISA test system, was approved by the FDA for screening of blood donors and 
was licensed in December 2006 (Gorlin J et al., 2008). Recently, specific diagnostic 
serum biomarkers for CD in asymptomatic patients have been identified, using mass 
spectrometric profiling. These include macrophage inflammatory protein-1alpha (MIP-
1alpha), C3a anaphylatoxin, and unusually truncated forms of fibronectin, apolipoprotein 
A1 (ApoA1), and C3 (Ndao M et al., 2010). However, it still remains to be seen how 
effective these biomarkers can be in accurate screening and diagnosis of CD. 
1.2.4. Potential role of biomarkers in cardiomyopathy due to Chagas’ disease 
Cardiac involvement is the most common manifestation of chronic CD, and represents the 
major cause of mortality. However, its diagnosis is still based on nonspecific criteria with 
poor sensitivity. Early identification of patients with cardiomyopathy due to CD is 
desirable, as early therapy may improve prognosis. Plasma BNP concentration and plasma 
angiotensin converting enzyme-2 (ACE-2) activity are important biomarkers for HF, and 
can potentially be used for diagnostic and prognostic purposes in patients with CD 
(Moreira Mda C et al., 2008; Wang Y et al., 2010). Infact, BNP and ACE-2 have additive 
predictive value, and may be used in combination for prediction of HF in patients with 
CD. Similarly, inflammatory biomarkers can play a vital role in early diagnosis, as  
inflammation of heart is a major hallmark of cardiomyopathy due to CD, and may be 
present even in the absence of HF. Plasma levels of TNF alpha, IL-6, and endothelin 1, 
are elevated in patients with CD (Garcia-Alvarez A et al., 2010). Thus, they may be used 
as biomarkers for early diagnosis and treatment of patients with cardiac involvement due 
to CD. 
Introduction   15 
 
1.3. Cytokines – a brief overview 
Cytokines are small proteins that play an important role in intercellular signaling. They 
are produced by various cell types in the body including lymphocytes (lymphokines) and 
monocytes (monokines). Cytokines which are produced by leukocytes and in turn act on 
other leukocytes are called interleukins. Cytokines can exert their effect on cells that 
produce them (autocrine effect), on neighbouring cells (paracrine effect), and also on 
remote cells in the body (endocrine effect) (Zhang JM and An J, 2007). 
Cytokines regulate host responses to infection, immune responses, inflammation, and 
trauma. Some cytokines are involved in the up-regulation of inflammatory reactions. 
These are known as pro-inflammatory cytokines and are mainly produced by activated 
macrophages. TNF alpha and IL-1 are some examples of pro-inflammatory cytokines 
(Dinarello CA et al., 2000). Anti-inflammatory cytokines, on the other hand, are immune-
regulatory molecules that control the pro-inflammatory cytokine response. Such cytokines 
work together with specific cytokine inhibitors and soluble cytokine receptors to regulate 
the immune response in human body. Some of the anti-inflammatory cytokines present in 
the body include IL-1 receptor antagonist, IL-4, IL-6, and IL-10 (Opal SM and DePalo 
VA, 2000). 
Chemokines are a family of small cytokines secreted by cells. Some of these chemokines 
actively participate in the inflammatory response to an infection, attracting immune cells 
to the site of inflammation (Mélik-Parsadaniantz S and Rostène W, 2008). 
There are certain cytokines also present in the human body that exert diverse immune 
effects. Leukemia inhibitory factor (LIF), for example, is one such cytokine. In some 
conditions, LIF can act as a pro-inflammatory cytokine, inducing the production of other 
pro-inflammatory cytokines and monocyte chemo-attractants, while in other conditions it 
can suppress inflammation and act as an anti-inflammatory cytokine (Alexander HR et 
al., 1994). 
1.4. Aims of Study 
CD is one of the most important neglected tropical diseases in the world. It continues to 
be a source of great financial and social burden in Latin America and now is a major 
concern for countries outside Latin America due to rising risk of non-vectorial 
transmission by blood transfusion and organ transplantation. Thus, there is a growing 
need for development of improved serological and molecular tests for effective screening 
in blood banks and hospitals, and for accurate diagnosis, that would be essential to initiate 
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appropriate therapy. Moreover, reliable prognostic tools are required for developing risk 
stratification models for mortality in CD patients that would help in selecting the best 
possible treatment regimen. 
Keeping in view the inflammatory nature of CD, this study investigated the possible role 
of serum cytokines as biomarkers for prediction and prognosis of CD. The serum levels of 
21 different inflammatory cytokines were measured in a group of patients with CD and 
then compared with those measured in patients with DCM from other causes, and with 
control subjects. The inflammatory cytokines that were studied included:interleukin-
1alpha (IL-1alpha), interleukin-16 (IL-16), interleukin-18 (IL-18), macrophage-colony 
stimulating factor (M-CSF), macrophage migration inhibitory factor (MIF), stem cell 
factor (SCF), stem cell growth factor beta (SCGF beta), tumour necrosis factor beta (TNF 
beta), TNF-related apoptosis inducing ligand (TRAIL), interleukin-12p40 (IL-12p40), 
interleukin-2 receptor alpha (IL-2R alpha), interleukin-3 (IL-3), hepatocyte growth factor 
(HGF), interferon-alpha2 (IFN-alpha2), beta-nerve growth factor (beta-NGF), leukemia 
inhibitory factor (LIF), cutaneous T-cell attracting chemokine (CTACK), growth related 
oncogene alpha (GRO alpha), monocyte chemo-attractant protein-3 (MCP-3), monokine 
induced by interferon gamma (MIG), and stromal derived factor-1alpha (SDF-1alpha). 
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2. Materials and Methods 
2.1. Instruments 
Bio-Plex® or Luminex system   Bio-Rad Laboratories, Hercules, 
94547, CA, USA. 
Bio-Plex validation kit 
Bio-Plex calibration kit 
Bio-Plex Pro II wash station 
Bio-Plex Pro flat bottom 
plates (40, 1×96-well plates) 
Microtiter plate shaker BioTech, Ritterstieg,Germany. 
Vortexer VWR, Leuven, USA. 
Reagent reservoirs, 25 ml 
(for captured beads and 
detection antibodies) 
Reagent reservoir, 50 ml Greiner Bio-One, Frickenhausen, 
(for reagent and buffers) Germany. 
Pall Life Science Acrodisc: 
25 mm PF syringe filter  
(0.8/0.2 µm Supor membrane) 
Ultrasonographic system Sequoia C256, Acuson, Acuson Inc, 
 Mountain View, CA, USA. 
2.2. Materials 
Bio-Plex Pro assay kit: Bio-Rad Laboratories, Hercules, CA, USA 
Coupled magnetic beads (10×) 
Detection Antibodies (10×) 
Universal standard diluent 
Universal sample diluents 
Assay buffer 
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Wash buffer 
Detection antibody diluent 
Streptavidin-PE (100×) 
Filter plate (96-well) 
Sealing tape  
Tube holder 
 
Sterile distilled water 
Aluminium foil 
Absorbent paper towels 
Micro-centrifuge tubes (1.5 or 2 ml) 
2.3. Methods 
2.3.1. Patients 
The study was approved by the institutional review committee, and all patients gave written 
consent. The study population consisted of a prospective cohort of 142 subjects from the 
Heart Failure Center of the Felicio-Rocho Hospital, Brazil, enrolled between July 2001 and 
January 2005. Ninety- four (94) consecutively recruited patients with atleast two positive 
serologies for CD (Chagas group [CD]) and forty-eight (48) patients with negative serology 
for CD (Idiopathic DCM group) were studied and compared with twenty-five (25) adjusted 
gender- and age-matched healthy subjects. 
All clinical data was obtained by the same investigator and included the medical history, 
physical examination, and resting electrocardiogram. M-mode, two-dimensional, and Doppler 
echocardiographic measurements were performed with an ultrasonographic system (Sequoia 
C256, Acuson, Acuson Inc, Mountain View, CA) according to the recommendations of 
American Society of Echocardiography. Left ventricular systolic dysfunction was defined by 
a left ventricular ejection fraction (LVEF) of < 50% as assessed by transthoracic 
echocardiography (Teichholz method). 
Other structural cardiac diseases and co-morbidities were excluded by medical history, 
physical examination, electrocardiogram, M-mode, two-dimensional, and Doppler 
echocardiography, or coronary arteriography: valvular heart disease, coronary artery disease, 
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congenital disease, acute myocarditis, hypertensive disease, renal failure (plasma creatinine > 
0.2 mmol/L), chronic pulmonary disease, hepatic cirrhosis, active infections, and endocrine 
disease. Patients with ventricular dysfunction received standard pharmacologic therapy 
according to the New York heart association (NYHA) functional class and were clinically 
stable for at least 30 days. 
Patients with advanced refractory HF were considered as heart transplant candidates and listed 
for the procedure in the absence of any contraindication. The control group was composed of 
healthy subjects attending the hospital clinics for a physical check-up. They had no cardiac 
symptoms or history, no co-morbidities, and took no medication. 
The study patients were prospectively defined and subdivided into 5 groups: Group 1 (n = 46), 
CD without ventricular systolic dysfunction (LVEF > 50%); Group 2 (n = 25), CD with 
ventricular systolic dysfunction (LVEF < 50%) in NYHA classes I-II; Group 3 (n = 23), CD 
with ventricular systolic dysfunction (LVEF < 50%) in NYHA classes III-IV; Group 4 (n= 
22), DCM with ventricular systolic dysfunction (LVEF < 50%) in NYHA classes I-II; and 
Group 5 (n = 26), DCM with ventricular systolic dysfunction (LVEF < 50%) in NYHA 
classes III-IV. 
Patients were followed for incidences of cardiac death or heart transplant from the time the 
blood sample was obtained for measurement and analysis of cytokines until end points were 
reached or until the follow-up closing date in January 2006. The end point was defined as 
either heart transplantation or death. Long-term follow-up of each patient was conducted by 
medical visit or telephone interview every three months. For those hospitalized during follow-
up, the hospital records were reviewed. For all subjects who died, the nearest relative was 
contacted. 
2.3.2. Plasma sampling 
Ten milliliters of blood samples were taken from the antecubital vein of subjects and 
transferred into tubes containing ethylenediamine tetra-acetic acid (EDTA). Immediately after 
sampling, plasma was separated by centrifugation at 4000g for 10 minutes, and frozen at -
80°C for further analysis. To prepare each sample, 35µL of EDTA was taken and diluted 
with a sample diluent. Samples were kept on ice till they were ready for use. 
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2.3.3. Cytokines measurement 
Plasma concentrations of twenty-one (21) different human cytokines were measured using 
the Bio-Plex ProTM system that combined the principle of a sandwich immunoassay with the 
Luminex fluorescent-bead-based technology (Bio-Rad Laboratories) (Fu Q et al., 2010). An 
antibody directed against the desired cytokine, chemokine, or growth factor target is 
covalently coupled to internally dyed beads. The coupled beads are allowed to react with the 
sample containing the target bio-molecules. After a series of washes to remove the unbound 
protein, a bio-tinylated detection antibody which is specific to an epitope different from that 
of the capture antibody is added to the reaction. This results in the formation of a sandwich 
of antibodies around the cytokine, chemokine, or growth factor target. A streptavidin-
phycoerythrin (streptavidin-PE) reporter complex is then added to bind to the biotinylated 
detection antibodies on the bead surface. Data from the reaction are acquired using the Bio- 
plex system, and analyzed by Bio-Plex ManagerTM software. 
The Bio-Plex® system is built around three core components. The first is a system of 100 
unique fluorescently dyed beads (xMAP technology) that permit the simultaneous detection 
of up to 100 different types of molecules in a single well of a 96-well micro-plate. The 
second component is a flow cytometer with two lasers and associated optics to measure the 
different molecules bound to the surface of the beads. The third is a high-speed digital signal 
processor that efficiently manages the fluorescent data. 
2.3.4. Data acquisition and analysis 
Data from the reaction are acquired using the Bio- Plex® system (or Luminex system), a 
dual-laser, flow-based micro-plate reader system. The contents of the plate are drawn up 
into the reader. The lasers and associated optics detect the internal fluorescence of the 
individual dyed beads as well as the fluorescent reporter signal on the bead surface. This 
identifies each assay and reports the level of target protein in the sample. Intensity of 
fluorescence detected on the beads will indicate the relative quantity of the target bio-
molecules in the tested samples. A high-speed digital processor then manages the data 
output, which is further analyzed and presented as fluorescence intensity (FI) and target 
concentration on Bio-Plex ManagerTM software. Results were expressed in picograms per 
milliliter (pg/mL). 
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2.3.5. Missing values analysis 
Cases with missing values represent an important challenge, as discarding these cases from 
the analysis can significantly reduce the amount of data. When there are only few values 
that are missing then the standard method of list-wise deletion is relatively “safe”. However, 
this deletion may decrease the precision of calculated statistics as there is less information 
than originally planned. Therefore, the method of imputing can help by providing some 
surrogates of the missing values. This procedure provides multiple versions of the dataset, 
each containing its own set of imputed values (5 imputing datasets were used in this 
analysis). For statistical analysis, the parameter estimates for all of the imputed datasets are 
pooled, providing more accurate statistics. Missing values analysis was performed using 
IBM SPSS version 18. 
(Dr Niels Wessel [Charite, Berlin, Germany] supported and assisted in the statistical 
analysis.) 
2.3.5.1. Chagas’ disease 
Dataset contained 111 cases. 17 cases did not have any of the 21 parameters. They were all 
excluded from further analysis. Twelve values were imputed for 94 cases: 
IL-1alpha, IL-18, M-CSF, TNF beta, IL-12p40, IL-3, IFN-alpha2, beta-NGF, LIF, GRO 
alpha, MCP-3, and SDF-1alpha were imputed. 
Other nine values were not necessary to impute as they were available for all cases. 
2.3.5.2. Dilated cardiomyopathy 
Dataset contained 62 cases. 14 cases did not have any of the 21 parameters. They were 
excluded from further calculations. Five values were imputed for 48 cases: 
IL-1alpha, TNF beta, LIF, GRO alpha, and MCP-3 were imputed. 
Other sixteen values were fully available for all 48 patients. 
2.3.6. Statistical analysis 
The plasma concentrations of all 21 cytokines were expressed as mean ± standard error of 
the mean (SEM). The associations between concentrations of various cytokines and clinical 
variables were tested using Mann-Whitney U test. As the data was normally distributed, 
Pearson’s correlation coefficient (r) was used to analyze the correlation between the 
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investigated cytokines in CD and DCM patient groups and various echocardiographic 
parameters – they were tested against the null hypothesis that the correlation coefficient is 0. 
A p value < 0.05 was defined as significant. Kaplan-Meier curves were also drawn to 
compare the survival or necessity for heart transplantation of patients with CD and DCM 
depending on different concentrations of cytokines. 
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3. Results 
3.1. Patients 
Baseline characteristics of patients and control subjects according to the NYHA functional 
class, ECG, echocardiographic parameters, and medications are given in table 1. The mean 
duration of follow-up was 36.9 months (range: 13-54 months). At the end of study, the 
survival status of all patients was known; 30 patients had died and 12 patients had received a 
heart transplant. Of these, 18 patients with CD and 12 patients with DCM had died. While 6 
patients each from CD and DCM groups had received a heart transplant. 
Systolic blood pressure was significantly altered in patients in the CD group and in patients 
in the DCM group with advancing HF in comparison with the control group or patients with 
CD without ventricular systolic dysfunction. Table 1 also illustrates increased impairment 
of cardiac function in patients with CD and in patients with DCM with increasing NYHA 
class. 
All patients with ventricular dysfunction received maximal medical therapy according to 
their functional classes and the treatment guideline recommendations, as shown in table 1. 
Almost all patients with ventricular dysfunction were given ACEIs or ARBs; 22 patients 
with DCM were taking carvedilol, but only 3 patients with CD were receiving beta blocker 
therapy. This lack in beta blocker treatment in patients with CD, although recommended by 
all guidelines for the treatment of HF, resulted from missing experience with beta blockers 
in CD because all the major trials on HF exclude patients with CD. Moreover, this disease is 
very often characterized by bradyarrhythmias and advanced atrioventricular block, which 
makes it difficult to use beta blockers (Braga JC et al., 2006; Wang Y et al., 2010). 
3.2. Data analysis 
Plasma concentrations of 21 different cytokines were measured in control subjects, in CD 
patients, and in DCM patients (Table 2). The CD patients were divided into asymptomatic 
(0), NYHA classes I-II, and NYHA classes III-IV. While DCM patients were divided into 
NYHA classes I-II and NYHA classes III-IV. Cytokines were also subdivided into 4 groups: 
pro-inflammatory cytokines, anti-inflammatory cytokines, cytokines with diverse immune 
effects, and chemokines. 
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Groups       Control Chagas’ disease DCM 
  0 NYHA I-II NYHA III-IV NYHA I-II NYHA III-IV 
 (n = 25) (n = 46) (n = 25) (n = 23) (n = 22) (n = 26) 
       
Age (years) 53.9 ± 2.9 52.0 ± 1.5 50.6 ± 2.3 48.9 ± 1.9 49.8 ± 3.6 47.2 ± 2.4 
Sex 
   Male 
   Female 
 
12 
13 
 
11 
35 
 
10 
15 
 
13 
10 
 
14 
8 
 
16 
10 
SBP (mmHg) 121.0 ± 2.1 125.7 ± 2.1 110.3 ± 2.2### 98.7 ± 2.9***/### 112.8 ± 2.8# 95.9 ± 4.6***/### 
DBP (mmHg) 76.4 ± 0.98 78.9 ± 1.2 73.3 ± 1.3 70.3 ± 1.8### 73.9 ± 1.5 70.8 ± 1.8### 
HR (beats/min) 73.6 ± 1.2 69.5 ± 1.3 69.8 ± 2.1 75.0 ± 2.5 72.9 ± 2.0 83.2 ± 2.2**/### 
ECG       
Normal/Abnormal 25/0 13/33 0/25 0/23 0/22 0/26 
Pacemaker 0 4 6 3 1 1 
ECHO       
   LVEF (%) 
 
   LVEF>50%/<50% 
 
67.5 ± 1.1 
 
46/0 
37.8 ± 2.0### 
 
2/23 
24.5 ± 1.5### 
 
0/23 
37.2 ± 2.2### 
 
0/22 
23.4 ± 1.3### 
 
0/26 
 
   LVDD (mm) 
 
 
51.9 ± 1.0 
 
62.7 ± 1.6### 
 
70.9 ± 1.3### 
 
64.7 ± 2.1### 
 
74.9 ± 2.0### 
 
   LVSD (mm) 
 
 
32.6 ± 0.90 
 
50.6 ± 1.8### 
 
62.1 ± 1.3### 
 
52.8 ± 2.1### 
 
66.6 ± 2.1### 
` 
   LVEDV (ml) 
 
 
131.5 ± 6.8 
 
204.1 ± 12.0# 
 
303.4 ± 20.2### 
 
217.7 ± 16.8# 
 
358.4 ± 36.3### 
   LVESV (ml)  41.8 ± 3.0 109.8 ± 10.7## 209.5 ± 10.7### 137.5 ± 13.5### 
 
256.9 ± 28.8### 
 
Pharmacotherapy       
   No medication 25 31 1 - - - 
   ACEI - 3 22 21 20 15 
   ß-blocker - 1 2 - 14 8 
   ARB - - 1 1 2 8 
   Amiodarone - 4 5 6 3 2 
   Diuretic - 3 17 21 19 25 
   Digoxin - 2 11 19 12 22 
   Spironolactone - - 4 14 13 19 
   Anticoagulant - 3 2 6 2 8 
 
Cytokines Control CD  0 CD I-II CD III-IV DCM I-II DCM III-IV 
 Mean 
 
SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
IL-1alpha 14.63 3.847 15.38 2.889 16.19 4.152 12.71 3.570 13.78 3.815 13.79 5.118 
Table 1. Patient characteristics. Data given as mean ± S.E.M. ** p < 0.01, *** p < 0.001 vs. Control; # p < 0.05, 
## p < 0.01, ### p < 0.001 vs. Chagas group 0. DBP = Diastolic blood pressure, HR = Heart rate, LVDD = Left 
ventricular diastolic diameter, LVEDV = Left ventricular end-diastolic volume, LVESV = Left ventricular end-
systolic volume, LVSD = Left ventricular systolic diameter, SBP = Systolic blood pressure. 
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Cytokines Control CD  0 CD I-II CD III-IV DCM I-II DCM III-IV 
 Mean 
 
SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM 
IL-1alpha 14.63 3.847 15.38 2.889 16.19 4.152 12.71 3.570 13.78 3.815 13.79 5.118 
IL-16 319.6 28.94 309.7 19.14 322.5 19.16 344.6 30.24 374.9 30.76 354.8 22.25 
IL-18 139.1 22.19 146.2 21.29 134.4 20.60 171.2 28.60 182.9 31.81 157.5 30.18 
M-CSF 28.02 5.254 24.71 4.285 28.01 4.860 35.55 6.818 27.22 6.688 26.97 5.445 
MIF 162.9 19.17 206.1 24.25 189.3 26.30 324.5 64.53 171.0 21.61 196.9 20.72 
SCF 195.0 18.49 196.0 16.62 201.5 20.89 223.1 26.91 219.9 26.05 228.4 23.00 
SCGF beta 24,130 4,856 22,943 2,638 26,103 5,226 46,231 9,495 28,944 6,168 45,903 7,705 
TNF beta 17.04 3.293 14.88 2.330 15.35 2.873 12.90 2.438 18.48 3.788 14.62 4.146 
TRAIL 148.0 16.86 152.7 11.28 182.9 24.80 192.3 26.14 170.0 21.80 186.1 28.47 
IL-12p40 130.6 19.74 171.9 17.18 178.5 27.67 260.3 50.42 172.0 26.48 246.0 41.79 
IL-2R alpha 100.9 10.32 102.7 7.300 104.6 12.28 123.0 15.98 95.63 7.602 125.1 12.53 
IL-3 73.29 8.889 82.60 7.425 79.53 8.999 91.00 10.34 84.69 9.154 98.01 9.559 
HGF 240.2 27.36 242.5 16.88 284.0 36.50 649.0 91.38 321.4 30.76 550.5 54.94 
IFN-alpha2 57.79 4.081 57.73 3.088 58.36 3.912 63.97 5.431 61.84 3.949 69.96 3.476 
beta-NGF 18.30 4.129 16.28 2.615 19.91 4.375 22.51 4.439 22.44 5.592 26.23 5.866 
LIF 76.14 4.100 51.46 7.563 53.96 9.145 44.19 9.091 54.69 11.09 56.71 10.79 
CTACK 1,436 77.27 1,317 70.09 1,519 121.4 1,798 220.3 1,504 100.5 1,480 100.5 
GRO alpha 45.48 8.952 42.44 6.218 48.10 6.131 56.01 7.865 39.94 4.866 42.47 4.872 
MCP-3 19.74 3.743 17.26 1.462 15.96 2.099 24.72 4.895 15.75 2.846 23.65 3.198 
MIG 808.4 147.4 1224 162.7 1,695 324.3 2,329 411.5 832.8 95.29 1,307 211.3 
SDF-1alpha 138.6 21.32 173.7 18.30 178.8 26.58 214.2 35.44 164.7 24.17 266.5 29.98 
 
Table 2. Plasma concentrations of cytokines in control, CD, and DCM groups expressed as mean ± standard 
error of the mean (SEM). All values are expressed in pg/mL. 
3.2.1. Pro-inflammatory cytokines 
Pro-inflammatory cytokines in this study included: IL-1alpha (Piper SC et al., 2013), IL-16 
(Reikeras O et al., 2014), IL-18 (Piper SC et al., 2013), M-CSF (Vincent VA et al., 2002), 
MIF (Al-Abed Y et al., 2005), SCF (Patella V et al., 1998), SCGF beta (Stein A et al., 
2013), TNF beta (Cassatella MA et al., 1993), TRAIL (Collison A et al., 2009; Song S et 
al., 2011;), IL-12p40 (Croxford AL et al., 2014; Chowdhury IH et al., 2014), and IL-2R 
alpha (Won HY et al., 2010). 
3.2.1.1. Interleukin-1alpha (IL-1alpha) 
Fig. 1 shows mean plasma levels of IL-1alpha in control, CD and DCM groups. The mean 
IL-1alpha concentration in control subjects was measured to be 14.63±3.847 pg/mL. As 
shown, there are slight, insignificant increases in plasma concentrations of IL-1alpha in CD 
0 (15.38±2.889 pg/mL) and CD I-II (16.19±4.152 pg/mL) groups when compared to control. 
On the other hand, mean plasma concentration of IL-1alpha is decreased in CD patients with 
Results  26 
 
NYHA III-IV (12.71±3.570 pg/mL) compared with control group but this is again 
insignificant. Mean plasma levels of IL-1alpha in DCM patients with NYHA I-II and 
NYHA III-IV do not differ much from that in control subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Plasma concentration of IL-1alpha in controls (n = 18); in patients with CD divided in asymptomatic 
(0) (n = 35), NYHA classes I-II (n = 18), and NYHA classes III-IV (n = 19); and in patients with DCM divided 
in NYHA classes I-II (n = 11) and NYHA classes III-IV (n = 15). Data is given as mean ± SEM. Hu IL-1alpha, 
Human interleukin-1 alpha. 
3.2.1.2. Interleukin-16 (IL-16) 
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Figure 2. Plasma concentration of IL-16 in controls (n = 25); in patients with CD distributed in asymptomatic 
(0) (n = 46), NYHA classes I-II (n = 25), and NYHA classes III-IV (n = 23); and in patients with DCM divided 
in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± SEM. 
Mean plasma IL-16 concentration in control group was measured to be 319.6±28.94 pg/mL. 
As shown in fig. 2, there is no significant alteration in plasma concentration of IL-16 in CD 
patients when compared to the control population. There is a slight elevation in mean 
plasma level of IL-16 in DCM I-II group (374.9±30.76 pg/mL) but this is again statistically 
not significant. 
3.2.1.3. Interleukin-18 (IL-18) 
Fig. 3 below does not demonstrate any significant trend in variation of plasma IL-18 levels 
in either CD or DCM patients. Although there is an increase in mean IL-18 concentration in 
CD patients with NYHA III-IV (171.2±28.60 pg/mL) compared to control population 
(139.1±22.19 pg/mL), and a further increase is also observed in DCM patients with NYHA 
I-II (182.9±31.81 pg/mL) compared to CD III-IV group, all these changes are statistically 
insignificant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Plasma concentration of IL-18 in controls (n = 34); in patients with CD distributed in asymptomatic 
(0) (n = 43), NYHA classes I-II (n = 24), and NYHA classes III-IV (n = 27); and in patients with DCM divided 
in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 24). Data is given as mean ± SEM. 
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3.2.1.4. Macrophage-colony stimulating factor (M-CSF) 
There is a visible pattern of increase in mean plasma M-CSF concentration in CD patients as 
we move from asymptomatic CD 0 group (24.71±4.285 pg/mL) towards CD III-IV group 
(35.55±6.818 pg/mL), but it still does not represent a significant change. On the other hand, 
mean plasma levels of M-CSF in DCM patients remain unaltered compared to control group 
(28.02±5.254 pg/mL). 
 
 
 
 
 
  
 
 
 
Figure 4. Plasma concentration of M-CSF in controls (n = 25); in patients with CD distributed in 
asymptomatic (0) (n = 46), NYHA classes I-II (n = 25), and NYHA classes III-IV (n = 23); and in patients 
with DCM divided in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± 
SEM. 
3.2.1.5. Macrophage migration inhibitory factor (MIF) 
The average concentration of MIF in the control group is 162.9±19.17 (pg/mL). As shown 
in fig. 5, mean plasma levels of MIF are higher in CD patients compared with the control 
population. In fact, there is a significant increase in MIF levels in CD patients with NYHA 
III-IV (324.5±64.53 pg/mL) compared to control population (p < 0.05). On the other hand, 
there is a significant decrease in MIF levels in DCM patients with NYHA I-II (171.0±21.61 
pg/mL) in comparison to CD patients with NYHA III-IV (p < 0.05). 
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Figure 5. Plasma concentration of MIF in controls (n = 25); in patients with CD distributed in asymptomatic 
(0) (n = 46), NYHA classes I-II (n = 24), and NYHA classes III-IV (n = 23); and in patients with DCM divided 
in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± SEM. * p < 0.05 vs 
control. 
3.2.1.6. Stem cell factor (SCF) 
 
 
 
 
 
 
 
 
Figure 6. Plasma concentration of SCF in controls (n = 25); in patients with CD distributed in asymptomatic 
(0) (n = 46), NYHA classes I-II (n = 25), and NYHA classes III-IV (n = 23); and in patients with DCM divided 
in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± SEM. 
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The mean plasma SCF concentration in control group is 195.0±18.49 pg/mL. The average 
concentration of SCF in asymptomatic patients (CD 0) remains unaltered compared to 
control population. Patients in CD III-IV group show a more visible increase in plasma SCF 
levels (223.1±26.91 pg/mL) compared to control. Similarly, there is also an increase in 
plasma SCF concentration in DCM patients with NYHA I-II (219.9±26.05 pg/mL) and 
NYHA III-IV (228.4±23.00 pg/mL), but no statistical difference is detected in any of the 
above groups. 
3.2.1.7. Stem cell growth factor beta (SCGF beta) 
The average concentration of SCGF beta in control population is 24,130±4,856 pg/mL. 
Asymptomatic CD patients are characterized by unaltered SCGF beta levels (22,943±2,638 
pg/mL). Although SCGF beta levels tend to rise in CD and DCM patients with NYHA 
classes I-II, no statistical difference is detected in any of the groups. However, there is a 
significant increase in plasma SCGF beta concentrations in both CD and DCM patients with 
NYHA classes III-IV in comparison to CD patients that are asymptomatic (p < 0.05). 
 
 
 
 
 
 
 
 
Figure 7. Plasma concentration of SCGF beta in controls (n = 25); in patients with CD distributed in 
asymptomatic (0) (n = 46), NYHA classes I-II (n = 25), and NYHA classes III-IV (n = 23); and in patients 
with DCM divided in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± 
SEM. * p < 0.05 vs CD 0. 
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3.2.1.8. Tumour necrosis factor beta (TNF beta) 
Fig. 8 shows a decrease in TNF beta levels in CD patients when compared to control, 
although no statistical difference is reported. The average TNF beta concentration in control 
group is 17.04±3.293 pg/mL. In DCM patients with NYHA I-II (18.48±3.788 pg/mL), the 
mean plasma TNF beta concentration is slightly higher than in control and CD groups. 
Further, there is a decrease in TNF beta levels in DCM III-IV group (14.62±4.146 pg/mL) 
compared to DCM I-II. 
 
 
 
 
 
 
 
 
 
Figure 8. Plasma concentration of TNF beta in controls (n = 14); in patients with CD distributed in 
asymptomatic (0) (n = 36), NYHA classes I-II (n = 19), and NYHA classes III-IV (n = 17); and in patients 
with DCM divided in NYHA classes I-II (n = 11) and NYHA classes III-IV (n = 19). Data is given as mean ± 
SEM. 
3.2.1.9. TNF-related apoptosis inducing ligand (TRAIL) 
As shown in fig. 9, the mean plasma TRAIL levels in both CD and DCM patients are higher 
as compared to in control group (148.0±16.86 pg/mL). Within the CD and DCM groups as 
well, there is a progressive increase in mean TRAIL concentrations as we move to NYHA 
classes of higher values. The average concentration of TRAIL in CD III-IV patients is 
192.3±26.14 pg/mL, while in DCM III-IV patients it is 186.1±28.47 pg/mL. There is still no 
statistical significance observed in any of the groups. 
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Figure 9. Plasma concentration of TRAIL in controls (n = 25); in patients with CD distributed in 
asymptomatic (0) (n = 46), NYHA classes I-II (n = 25), and NYHA classes III-IV (n = 23); and in patients 
with DCM divided in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± 
SEM. 
3.2.1.10. Interleukin-12p40 (IL-12p40) 
 
 
 
 
 
 
 
 
Figure 10. Plasma concentration of IL-12p40 in controls (n = 25); in patients with CD distributed in  
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asymptomatic (0) (n = 46), NYHA classes I-II (n = 24), and NYHA classes III-IV (n = 23); and in patients 
with DCM divided in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± 
SEM. 
Fig. 10 shows that the mean plasma IL-12p40 concentrations in both CD and DCM patients 
are higher compared to control population (130.6±19.74 pg/mL). There is a marked increase 
in IL-12p40 levels in both CD patients with NYHA III-IV (260.3±50.42 pg/mL) and in 
DCM patients with NYHA III-IV (246.0±41.79 pg/mL) when compared to control group, 
although no statistical difference is seen in any of the groups. 
3.2.1.11. Interleukin-2 receptor alpha (IL-2R alpha) 
CD patients without systolic dysfunction are characterized by unaltered plasma levels of IL-
2R alpha in comparison to control group (100.9±10.32 pg/mL). However, there is some 
increase in IL-2R alpha concentration in both CD and DCM patients with NYHA III-IV 
stages compared to control population. The average concentration of IL-2R alpha in CD III-
IV patients is 123.0±15.98 pg/mL, while in DCM III-IV patients it is measured to be 
125.1±12.53 pg/mL. 
 
 
 
 
 
 
 
 
Figure 11. Plasma concentration of IL-2Rα in controls (n = 25); in patients with CD distributed in 
asymptomatic (0) (n = 46), NYHA classes I-II (n = 24), and NYHA classes III-IV (n = 23); and in patients 
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with DCM divided in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± 
SEM. 
3.2.2. Anti-inflammatory cytokines 
Two different anti-inflammatory cytokines were investigated in present study: IL-3 
(Kovalchin J et al., 2010; Srivastava RK et al., 2011) and HGF (Mizuno S and Nakamura T 
et al., 2012; Kusunoki H et al., 2014). 
3.2.2.1. Interleukin-3 (IL-3) 
Fig. 12 shows increased plasma concentrations of IL-3 in CD and DCM patients in 
comparison to control group (73.29±8.889 pg/mL). The IL-3 levels in CD III-IV patients 
(91.00±10.34 pg/mL) are higher compared to in CD 0 (82.60±7.425 pg/mL) and CD I-II 
patients (79.53±8.999 pg/mL). Similarly, DCM patients with NYHA III-IV (98.01±9.559 
pg/mL) are characterized by increased IL-3 levels in comparison to DCM patients with 
NYHA I-II (84.69±9.154 pg/mL), but there is no statistical significance relating to any of 
the groups above. 
 
 
 
  
 
 
 
 
 
Figure 12. Plasma concentration of IL-3 in controls (n = 24); in patients with CD distributed in asymptomatic 
(0) (n = 45), NYHA classes I-II (n = 24), and NYHA classes III-IV (n = 22); and in patients with DCM divided 
in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± SEM. 
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3.2.2.2. Hepatocyte growth factor (HGF) 
The average concentration of HGF in control population was measured to be 240.2±27.36 
pg/mL. Asymptomatic CD patients (242.5±16.88 pg/mL) and those belonging to NYHA 
class I-II showed unaltered HGF levels compared to control group. However, the plasma 
levels of HGF were significantly increased in CD and DCM patients with NYHA III-IV 
when compared to control and asymptomatic CD patients (p < 0.001). Mean concentration 
of HGF in CDIII-IV group was 649.0±91.38 pg/mL, while in DCM III-IV group it was 
measured to be 550.5±54.94 pg/mL. 
 
 
 
 
 
 
 
 
 
Figure 13. Plasma concentration of HGF in controls (n = 25); in patients with CD distributed in asymptomatic 
(0) (n = 46), NYHA classes I-II (n = 25), and NYHA classes III-IV (n = 23); and in patients with DCM divided 
in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± SEM. *** p < 0.001 
vs control and CD 0. 
3.2.3. Cytokines with diverse immune effects 
In this study, there were three cytokines with diverse immune effects: IFN-alpha2 (Tarhini 
AA et al., 2012; Levin D et al., 2014), beta-NGF (Gaspersic R et al., 2010; Peters EM et al., 
2011; Prencipe G et al., 2014) and LIF (Borish L and Rocklin R et al., 1992; Alexander H et 
al., 1994). 
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3.2.3.1. Interferon-alpha2 (IFN-alpha2) 
Plasma IFN-alpha2 levels in asymptomatic CD patients and in NYHA class I-II patients 
remain unaltered when compared to the individuals in control group (57.79±4.081 pg/mL). 
In CD and DCM patients with NYHA III-IV, there is some increase in IFN-α2 
concentrations compared to control but there is no statistical significance detected in any of 
the groups. 
 
 
 
 
 
 
 
 
 
Figure 14. Plasma concentration of IFN-alpha2 in controls (n = 25); in patients with CD distributed in 
asymptomatic (0) (n = 45), NYHA classes I-II (n = 24), and NYHA classes III-IV (n = 23); and in patients 
with DCM divided in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± 
SEM. 
3.2.3.2. Beta-nerve growth factor (beta-NGF) 
Mean plasma concentration of beta-NGF in control population was measured to be 
18.30±4.129 pg/mL. Fig. 15 shows a steady rise in beta-NGF levels in CD patients as we 
move from asymptomatic group (16.28±2.615 pg/mL) towards NYHA I-II (19.91±4.375 
pg/mL) and then NYHA III-IV (22.51±4.439 pg/mL). Likewise, there is also an increase in 
beta-NGF levels in DCM patients when we move from NYHA I-II (22.44±5.592 pg/mL) to 
NYHA III-IV (26.23±5.866 pg/mL), although no statistical difference could be detected in 
any of the groups. 
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Figure 15. Plasma concentration of beta-NGF in controls (n = 25); in patients with CD distributed in 
asymptomatic (0) (n = 46), NYHA classes I-II (n = 24), and NYHA classes III-IV (n = 23); and in patients 
with DCM divided in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± 
SEM. 
3.2.3.3. Leukemia inhibitory factor (LIF) 
 
 
 
 
 
 
 
 
Figure 16. Plasma concentration of LIF in controls (n = 08); in patients with CD distributed in asymptomatic 
(0) (n = 20), NYHA classes I-II (n = 15), and NYHA classes III-IV (n = 14); and in patients with DCM divided 
in NYHA classes I-II (n = 11) and NYHA classes III-IV (n = 12). Data is given as mean ± SEM. 
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LIF shows a trend which is different from those shown by cytokines mentioned above. In 
this case as shown in fig. 16, mean plasma LIF levels in both CD and DCM patients are 
decreased compared to control group (76.14±4.100 pg/mL), although no statistical 
difference is observed in any of the groups. The mean plasma concentration of LIF in CD 
patients with NYHA III-IV is 44.19±9.091 pg/mL, while in DCM patients with NYHA III-
IV it is 56.71±10.79 pg/mL. 
3.2.4. Chemokines 
Five different chemokines were investigated in present study: CTACK (Meyer N et al., 
2014; Wang F et al., 2014), GRO alpha (Nenseter MS et al., 2014; Rohde G et al., 2014), 
MCP-3 (Gonzalez J et al., 2013), MIG (Soloski MJ et al., 2014; Jovic S et al., 2014), and 
SDF-1alpha (Naqasawa T et al., 2014; Karimabad MN and Hassanshahi G et al., 2014). 
3.2.4.1. Cutaneous T-cell attracting chemokine (CTACK) 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Plasma concentration of CTACK in controls (n = 25); in patients with CD distributed in 
asymptomatic (0) (n = 46), NYHA classes I-II (n = 25), and NYHA classes III-IV (n = 23); and in patients 
with DCM divided in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± 
SEM. * p < 0.05 vs CD 0. 
The average concentration CTACK in control group is 1436±77.27 pg/mL. Fig. 17 shows a 
progressive increase in plasma CTACK levels in CD patients as we move from 
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asymptomatic (0) group (1317±70.09 pg/mL) to CD I-II group (1519±121.4 pg/mL) and 
then to CDIII-IV group (1798±220.3pg/mL). CD patients with NYHA III-IV particularly 
show a significant rise in CTACK concentration in comparison to asymptomatic CD 
patients (p < 0.05). Plasma levels of CTACK in DCM patients with NYHA I-II (1504±100.5 
pg/mL) and NYHA III-IV (1480±100.5 pg/mL), however, remain unaltered when compared 
to control group. 
3.2.4.2. Growth related oncogene alpha (GRO alpha) 
The mean concentration of GRO alpha in control population is 45.48±8.952 pg/mL. As 
shown in fig. 18, mean GRO alpha levels rise steadily in CD patients as we move from 
asymptomatic CD (0) group (42.44±6.218 pg/mL) to CD I-II group (48.10±6.131 pg/mL) 
and then to CD III-IV group (56.01±7.865 pg/mL), although no statistical difference is 
noted in any of these groups. On the other hand, DCM patients show unaltered GRO alpha 
levels compared to control population. 
 
 
 
 
 
 
 
 
Figure 18. Plasma concentration of GRO alpha in controls (n = 20); in patients with CD distributed in 
asymptomatic (0) (n = 42), NYHA classes I-II (n = 22), and NYHA classes III-IV (n = 22); and in patients 
with DCM divided in NYHA classes I-II (n = 17) and NYHA classes III-IV (n = 22). Data is given as mean ± 
SEM. 
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3.2.4.3. Monocyte chemo-attractant protein-3 (MCP-3) 
The mean concentration of MCP-3 in control group is 19.74±3.743 pg/mL. As shown in fig. 
19, CD III-IV patients (24.72±4.895 pg/mL) are characterized by increased levels of plasma 
MCP-3 compared to control, CD 0 group (17.26±1.462 pg/mL) and CD I-II group 
(15.96±2.099 pg/mL). Similarly, DCM III-IV patients (23.65±3.198 pg/mL) also show 
raised levels of MCP-3 in comparison to control group and DCM I-II patients (15.75±2.846 
pg/mL). However, there is no statistical significance recorded in any of the groups. 
 
 
 
 
 
 
 
 
 
Figure 19. Plasma concentration of MCP-3 in controls (n = 18); in patients with CD distributed in 
asymptomatic (0) (n = 41), NYHA classes I-II (n = 23), and NYHA classes III-IV (n = 23); and in patients 
with DCM divided in NYHA classes I-II (n = 20) and NYHA classes III-IV (n = 22). Data is given as mean ± 
SEM. 
3.2.4.4. Monokine induced by interferon gamma (MIG) 
Fig. 20 shows an increase in mean plasma MIG levels in both CD and DCM patients when 
compared to control population (808.4±147.4 pg/mL). Within the CD group particularly, 
there is a marked increase in MIG levels as we move across to NYHA classes of higher 
values. The mean MIG concentration in CD III-IV patients (2,329±411.5 pg/mL) is 
significantly higher when compared to control group (p < 0.001) and asymptomatic CD 
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group (1224±162.7 pg/mL) (p < 0.05). MIG levels in CD III-IV patients are also markedly 
increased in comparison to DCM I-II patients (832.8±95.29 pg/mL) (p < 0.01). 
 
 
 
 
 
 
 
 
 
 
Figure 20. Plasma concentration of MIG in controls (n = 24); in patients with CD distributed in asymptomatic 
(0) (n = 46), NYHA classes I-II (n = 25), and NYHA classes III-IV (n = 22); and in patients with DCM divided 
in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 25). Data is given as mean ± SEM. *** p < 0.001 
vs control; ## p < 0.01 vs DCM I-II. 
3.2.4.5. Stromal derived factor-1alpha (SDF-1alpha) 
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Figure 21. Plasma concentration of SDF-1alpha in controls (n = 21); in patients with CD distributed in 
asymptomatic (0) (n = 44), NYHA classes I-II (n = 25), and NYHA classes III-IV (n = 23); and in patients 
with DCM divided in NYHA classes I-II (n = 22) and NYHA classes III-IV (n = 26). Data is given as mean ± 
SEM. * p < 0.05 vs control. 
As shown in fig. 21, mean SDF-1alpha levels in both CD and DCM patients are higher 
when compared to control group (138.6±21.32 pg/mL). Here again, there is a rise in SDF-
1alpha levels within CD group as we move across to NYHA classes of higher values. The 
average concentration of SDF-1alpha in asymptomatic CD patients is 173.7±18.30 pg/mL, 
while in CD patients with NYHA III-IV it is 214.2±35.44 pg/mL. In addition, there is a 
marked increase in mean SDF-1alpha levels in DCM patients with NYHA III-IV 
(266.5±29.98 pg/mL) when compared to control (p < 0.05). 
3.3. Evaluation of predictive and prognostic potency of stem cell growth 
factor beta 
3.3.1. Correlation with echocardiographic parameters 
 
 
 
 
 
 
 
 
 
Figure 22. Plasma SCGF beta concentration correlated to LVEF (%). 
A. In patients with CD (n = 47). 
B. In patients with DCM (n = 48). LVEF, left ventricular ejection fraction; r, Pearson’s correlation coefficient. 
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CD (NYHA I-IV) DCM (NYHA I-IV) 
r 
 
p r 
 
p 
 LVDD 0.0717 0.6357 0.1117 0.4600 
LVSD 0.1587 0.2921 0.1362 0.3668 
   LVEDV -0.0856 0.5946 0.0065 0.9679 
  LVESV 0.1707 0.2859 0.0814 0.6129 
Table 3. Correlation of plasma SCGF beta concentration to other echocardiographic parameters in CD and 
DCM patients (LVDD, left ventricular diastolic diameter; LVSD, left ventricular systolic diameter; LVEDV, 
left ventricular end diastolic volume; LVESV, left ventricular end systolic volume). 
A correlation analysis was performed to detect a possible correlation between SCGF beta 
and LVEF. Pearson’s correlation coefficient (r) was used to analyze the correlation between 
circulating SCGF beta concentration and echocardiograghic parameters in CD and DCM 
patients (NYHA I-IV).While SCGF beta was found to be significantly increased in CD and 
DCM patients with advanced HF (NYHA III-IV), its concentration was not significantly 
correlated with LVEF in patients with CD (p= 0.1011) (Fig. 22A) and in patients with DCM 
(p= 0.2923) (Fig. 22B). Similarly, a correlation analysis was also performed with other 
echocardiographic parameters (LVDD, LVSD, LVEDV, and LVESV), but SCGF beta 
concentration was not found to be significantly correlated to any of these parameters in both 
CD and DCM groups (Table 3). 
3.3.2. Receiver operating characteristic (ROC) and Kaplan Meier curves 
Receiver operating characteristic (ROC) curve was generated to find a cut-off value for 
plasma SCGF beta in CD patients (Fig. 23A). In order to find out whether the SCGF beta 
cut-off value (15,139 pg/mL) has any prognostic potency for mortality and heart 
transplantation of patients with CD and DCM, Kaplan-Meier curves were generated using 
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this cut-off value to divide the patients with CD and patients with DCM into two subgroups. 
Classical statistics, however, did not visualize any significant predictive value of SCGF beta 
plasma concentration for risk in lethality or the necessity for heart transplantation in both 
CD patients (NYHA I-IV) and DCM patients (Fig. 23B, C). 
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Figure 23. Receiver operating characteristic (ROC) and Kaplan-Meier curves (SCGF beta). 
A. ROC curve was used to define cut-off value for SCGF beta with best sensitivity and specificity based on 
CD patients in NYHA classes I-IV (Sensitivity: 56.00%; Specificity: 66.67%). The cut-off value was 
calculated to be 15,139 pg/mL. 
B, C. Kaplan-Meier survival curves were generated to compare percent survival in CD (B) and DCM (C) 
patients with SCGF beta higher or lower than cut-off value (cut-off = 15,139 pg/mL); p > 0.05. Statistical 
analysis was carried out by log-rank test. 
3.4. Evaluation of predictive and prognostic potency of hepatocyte 
growth factor 
3.4.1. Correlation with echocardiographic parameters 
 
 
 
 
 
 
 
 
Figure 24. Plasma HGF concentration correlated to LVEF (%). 
A. In patients with CD (n = 47). 
B. In patients with DCM (n = 48). 
As plasma HGF levels were significantly elevated in CD and DCM patients with advanced 
HF (Fig. 13), a correlation analysis was performed to find out whether the HGF levels were 
related to impaired cardiac function. While there was a significant correlation between 
circulating HGF and LVEF in CD patients with NYHA I-IV (p < 0.001) (Fig. 24A), there 
was no correlation in patients with DCM (p= 0.1041) (Fig. 24B). Moreover, the data 
summarized in table 4 shows that half of the echocardiographic parameters evidenced a 
correlation with the circulating HGF concentration in patients with CD, with the correlation 
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reaching significance for the parameters: LVEF (p= 0.0007), LVSD (p= 0.0167), and 
LVESV (p= 0.0241). However, there was no significant correlation between HGF and any 
echocardiographic parameters in patients with DCM. 
 
CD (NYHA I-IV) DCM (NYHA I-IV) 
r 
 
p r 
 
p 
 LVDD 0.2215 0.1391 0.1366 0.3652 
LVSD 0.3511 0.0167 0.1910 0.2036 
   LVEDV 0.1357 0.3975 0.2206 0.1657 
  LVESV 0.3518 0.0241 0.2848 0.0712 
Table 4. Correlation of plasma HGF concentration to other echocardiographic parameters in CD and DCM 
patients. 
3.4.2. Receiver operating characteristic (ROC) and Kaplan-Meier curves 
A 
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Figure 25. Receiver operating characteristic (ROC) and Kaplan-Meier curves (HGF). 
A. ROC curve was used to define cut-off value for HGF with best sensitivity and specificity based on CD 
patients in NYHA classes I-IV (Sensitivity: 77.55%; Specificity: 62.22%). The cut-off value was calculated to 
be 314.3 pg/mL. 
B, C. Kaplan-Meier survival curves were generated to compare percent survival in CD (B) and DCM (C) 
patients with HGF higher or lower than cut-off value (cut-off = 314.3 pg/mL); p > 0.05. Statistical analysis 
was carried out by log-rank test. 
The cut-off value for plasma HGF in CD patients was determined by constructing a ROC 
curve (Fig. 25A). In order to find out whether the HGF cut-off value (314.3 pg/mL) has any 
prognostic value for mortality and heart transplantation of patients with CD and DCM, 
Kaplan-Meier curves were generated using this cut-off value to divide the patients with CD 
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and patients with DCM into two subgroups. Classical statistics, however, did not visualize 
any significant predictive value of HGF plasma concentration for risk in lethality or the 
necessity for heart transplantation in both CD patients (NYHA I-IV) and DCM patients 
(Fig. 25B, C). 
3.5. Evaluation of prognostic and predictive potency of cutaneous T-cell 
attracting chemokine 
3.5.1. Correlation with echocardiographic parameters 
 
 
 
 
 
 
 
 
Figure 26. Plasma CTACK concentration correlated to LVEF (%). 
A. In patients with CD (n = 47). 
B. In patients with DCM (n = 48). 
A correlation analysis was performed between plasma CTACK concentration and LVEF. 
However, it was unable to show any significant correlation between the two parameters in 
patients with CD (p= 0.3907) (Fig. 26A) and in patients with DCM (p= 0.7483) (Fig. 26B). 
Further, a correlation analysis was also performed with other echocardiographic parameters 
like LVDD, LVSD, LVEDV, and LVESV, but plasma CTACK concentration was not found 
to be significantly correlated to any of these parameters in patients with CD and in patients 
with DCM (Table 5). 
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CD (NYHA I-IV) DCM (NYHA I-IV) 
r 
 
p r 
 
p 
 LVDD 0.0243 0.8729 0.0073 0.9616 
LVSD 0.0883 0.5595 -0.0179 0.9059 
   LVEDV -0.1545 0.3348 -0.1933 0.2259 
  LVESV 0.0310 0.8476 -0.1337 0.4047 
Table 5. Correlation of plasma CTACK concentration to other echocardiographic parameters in CD and DCM 
patients. 
3.5.2. Receiver operating characteristic (ROC) and Kaplan-Meier curves 
A 
 
Figure 27. Receiver operating characteristic (ROC) and Kaplan-Meier curves (CTACK). 
A. ROC curve, used to define cut-off value for CTACK with best sensitivity and specificity based on CD 
patients in NYHA classes I-IV (Sensitivity: 88%; Specificity: 37.5%). The cut-off value was calculated to be 
1,803 pg/mL. 
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B, C. Kaplan-Meier survival curves were constructed to compare percent survival in CD (B) and DCM (C) 
patients with CTACK higher or lower than cut-off value (cutoff = 1,803 pg/mL); p > 0.05. Statistical analysis 
was carried out by log-rank test. 
The ROC curve was generated to find a cut-off value for plasma CTACK in CD patients 
(Fig. 27A). To find out whether the CTACK cut-off value (1,803 pg/mL) has any prognostic 
potency for the lethality of patients with CD and DCM, Kaplan-Meier curves were 
generated using this cut-off value to divide the patients with CD and patients with DCM into 
two subgroups. Classical statistics did not visualize any significant predictive value of 
CTACK plasma concentration for risk in lethality or the necessity for heart transplantation 
in both CD patients (NYHA I-IV) and DCM patients (Fig. 27B, C). 
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3.6. Evaluation of prognostic and predictive potency of monokine 
induced by interferon gamma 
3.6.1. Correlation with echocadiographic parameters 
 
 
 
 
 
 
 
 
 
Figure 28. Plasma MIG concentration correlated to LVEF (%). 
A. In patients with CD (n = 46). 
B. In patients with DCM (n = 46). 
A correlation analysis was performed between plasma MIG concentration and LVEF. The 
analysis failed to reveal any significant correlation between the two parameters in CD 
patients (p= 0.2757) (Fig. 28A). However, there was a significant correlation detected 
between plasma MIG concentration and LVEF in patients with DCM (p= 0.0329) (Fig. 
28B). A correlation analysis was also done with other echocardiographic parameters such as 
LVDD, LVSD, LVEDV, and LVESV, but plasma MIG concentration was not found to be 
significantly correlated to any of these parameters in patients with CD and in patients with 
DCM (Table 6). Although plasma MIG levels were observed to be significantly increased in 
CD patients with advanced HF (Fig. 20), no significant correlation was found between MIG 
and echocardiographic parameters like LVEF in patients with CD. 
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CD (NYHA I-IV) DCM (NYHA I-IV) 
r 
 
p r 
 
p 
 LVDD 0.0699 0.6443 -0.0675 0.6557 
LVSD 0.1288 0.3937 -0.1054 0.4857 
   LVEDV -0.0233 0.8852 -0.1158 0.4708 
  LVESV 0.1061 0.5093 -0.1383 0.3885 
Table 6. Correlation of plasma MIG concentration to other echocardiographic parameters in CD and DCM 
patients. 
3.6.2. Receiver operating characteristic (ROC) and Kaplan-Meier curves 
A 
 
Figure 29. Receiver operating characteristic (ROC) and Kaplan-Meier curves (MIG). 
A. ROC curve, used to define cut-off value for MIG with best sensitivity and specificity based on CD patients 
in NYHA classes I-IV (Sensitivity: 79.17%; Specificity: 63.83%). The cut-off value was calculated to be 1,007 
pg/mL. 
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B, C. Kaplan-Meier survival curves were generated to compare percent survival in CD (B) and DCM (C) 
patients with MIG higher or lower than cut-off value (cut-off = 1,007 pg/mL); p > 0.05. Statistical analysis was 
carried out by log-rank test. 
ROC curve was generated to find a cut-off value for plasma MIG in CD patients (Fig. 
29A).To find out whether the MIG cut-off value (1,007 pg/mL) has any prognostic potency 
for mortality and heart transplantation of patients with CD and DCM, Kaplan-Meier curves 
were generated using this cut-off value to divide the patients with CD and patients with 
DCM into two subgroups. Classical statistics did not visualize any significant predictive 
value of MIG plasma concentration for risk in lethality or the necessity for heart 
transplantation in both CD patients (NYHA I-IV) and DCM patients (Fig. 29B, C). 
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3.7. Multivariate analysisBy using multivariate analysis, this study tried to 
investigate whether two or more cytokines together could demonstrate any predictive and 
prognostic potency in patients with CD and in patients with DCM due to idiopathic causes. 
3.7.1. Chagas’ disease 
Univariately, HGF was the only cytokine that was found to be significant. A forward 
stepwise discriminant analysis selected HGF and GRO alpha as 'the best' parameters and 
was able to separate 70.9% (cross-validated sensitivity/specificity of 31.8%/84.4%) 
survivors from the deceased. When imputing method was applied, more parameters for the 
multivariate analysis were allowed (when only one of 21cytokinesvalue was missing, then 
this patient was usually excluded from the discriminant listwise analysis). In the original 
data analysis, only 40.5% of patients were considered (N = 45). By imputing, this value 
was increased to 84.7% of patients (N = 94). Multivariately, the following parameters were 
selected: HGF and IL12p40 with a cross-validated separation of 81.9% 
(sensitivity/specificity of 92.9%/50.0%), an improvement of 11%. 
3.7.2. DCM 
Univariately, IL-16 was only found to be significant. In forward stepwise discriminant 
analysis, IL-16and IL-2R alpha were selected as 'best' parameters and was able to correctly 
classify 66.7% (cross-validated sensitivity/specificity of 74.2%/52.9%) survivors from the 
deceased. In the original data analysis, only 32.3% of patients (N = 20) were available. By 
imputing, it was increased to 77.4% of patients (N = 48). The DCM group now contained 
almost 80% of complete data. The best multivariate features were SDF-1alpha, SCF, and 
MIG, cross-validated with a separation of 77.1% (sensitivity/specificity of 76.5%/77.4%), 
an improvement of more than 10%. Statistically, this is very interesting as none of these 
three cytokine parameters were found to be significant univariately. 
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4. Discussion 
4.1. Role of inflammation in pathogenesis and progression of heart 
failure 
Chronic HF puts a major burden on public health, and its prognosis can be compared to that 
of different malignant diseases. HF is characterized by the activation of various 
inflammatory processes that result in increased levels of inflammatory markers such as IL-6 
and CRP (Anker SD and von Haehling S, 2004). This activation may occur due to several 
reasons such as myocardial damage, reduced cardiac output, and/or hemodynamic overload 
(Pasic J et al., 2003). A vicious circle is present between HF and inflammation as 
inflammatory markers have been found to be associated with worsening of cardiac function 
and poor prognosis. 
Cytokines belong to a group of relatively low molecular weight, pharmacologically active 
proteins. Some of the important pro-inflammatory cytokines implicated in the progression of 
HF are TNF alpha and IL-1. These cytokines are secreted by all nucleated cell types present 
in the myocardium, including the cardiac myocytes. The growing interest in understanding 
the role of inflammatory mediators in HF arises from the fact that many aspects of the 
syndrome of HF can be related to the known biological effects of inflammatory cytokines. 
When these cytokines are expressed at high concentrations, they are sufficient to mimic 
some aspects of the so-called heart failure phenotype, including progressive left ventricular 
(LV) dysfunction, pulmonary edema, LV remodeling, fetal gene expression, and 
cardiomyopathy. Therefore, the “cytokine hypothesis” for HF states that HF progresses, at 
least partially, due to the toxic effects of the endogenous cytokine cascades on the heart and 
the peripheral circulation (Andrade ZA, 1983). It emphasizes on the point that cytokines 
may not be the initial cause of HF, but rather that the over expression of cytokine cascades 
contribute to the disease progression of HF. Thus, the expression of cytokines, just like the 
expression of neurohormones, may represent a biological mechanism that is responsible for 
worsening HF. 
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4.2. Role of inflammation in pathogenesis and progression of Chagas’ 
disease 
Inflammatory processes mediated by cytokines also play a key role in the pathogenesis of 
CD. Activation of inflammation in CD differs from that in DCM from idiopathic causes and 
is associated with increased severity of HF (Mocelin AO et al., 2005). In chronic CD 
patients with cardiomyopathy, there is progressive and persistent inflammation of 
myocardial fibers that leads to gradual impairment of contractile function and dilatation of 
all four chambers of the heart. With time, the myocytes are gradually lost due to 
inflammatory tissue destruction, and the dead myocytes are then replaced by intense 
fibrosis, which predispose the patient to development of HF, ventricular arrhythmias, and 
other serious pathologies (Andrade ZA, 1983; Rassi A Jr et al., 2009). 
Mononuclear cellular infiltrate is present throughout the myocardium with vast areas of 
confluent fibrosis in CD but is not seen in idiopathic DCM (Rossi MA et al., 2003; Nunes 
VL et al., 2006). This widespread myocardial inflammatory infiltrate can lead to a more 
severe ventricular remodeling process, causing a rapid and severe onset HF, and ultimately 
death. Patients with HF due to CD, therefore, are associated with a poorer prognosis and 
outcome in comparison to patients with DCM from idiopathic causes (Pereira Nunes Mdo C 
et al., 2010; Barbosa AP et al., 2011). 
4.3. Role of cytokines in cardiac remodeling 
CD is characterized by progressive cardiac remodeling, which may finally result in DCM 
and congestive heart failure, the most serious manifestation of chronic CD. Ventricular 
remodeling includes various processes such as cardiomyocyte loss through necrosis or 
apoptosis, hypertrophic response of remaining cardiomyocytes, angiogenesis, and an 
architectural rearrangement of extracellular matrix (Cohn JN et al., 2000; Lamblin N et al., 
2005). Various studies indicate that endogenous repair mechanisms regulated by stem cells 
are involved in chronic cardiac remodeling. This in turn is coordinated by various types of 
cytokines, growth factors, and chemokines (Cui Y and Madeddu P, 2011; Fortini C et al., 
2011). For example, plasma levels of HGF, fibroblast growth factor (FGF), vascular 
endothelial growth factor (VEGF), and SDF-1alpha are significantly increased in HF 
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patients as compared to in healthy subjects (Fortini C et al., 2011). There is a possibility of 
using some of the cytokines as prognostic markers in HF patients. 
4.4. Inflammatory biomarkers in Chagas’ disease 
Specific local or systemic pathways of inflammation might be particularly active in patients 
with cardiomyopathy due to CD, and could be responsible for the variations observed in 
clinical course of disease, when compared to DCM from other causes (Mocelin AO et al., 
2005). By identifying such serum biomarkers that might be involved in regulation of these 
inflammatory pathways, we may be able to use them as tools for early diagnosis and 
prognosis of CD. As cardiomyopathy due to CD is associated with a poor prognosis, 
identifying patients accurately at an early stage of the disease may help in providing 
effective treatment and prevent the development of HF and thus early death. 
In this study, 21 different cytokines were investigated in both CD and idiopathic DCM 
patients. The serum levels of each of these cytokines were measured in both groups of 
patients to see if they were regulated and whether there was any difference in regulation 
from one group to the other. Out of the 21 different inflammatory cytokines that were 
investigated, 10 of them have been found to be regulated in patients with HF from various 
causes, according to the present literature. These include IL-1alpha (Munger MA et al., 
1996), IL-18 (von Haehling S et al., 2009), M-CSF (Hohensinner PJ et al., 2010), MIF (Liu 
Y et al., 2003), TRAIL (Niessner A et al., 2009), HGF (Rychli K et al., 2011), beta-NGF 
(Kaye DM et al., 2000), LIF (Hirota H et al., 2004), GRO alpha (Damas JK et al., 2000),and 
SDF-1alpha (Fortini C et al., 2011). 
This investigation demonstrated a number of cytokines, whose mean plasma concentrations 
were significantly increased in CD patients with advanced HF (NYHA III-IV) when 
compared to healthy subjects. These included: MIF, SCGF beta, HGF, CTACK, and MIG. 
In addition, cytokines like SCGF beta, HGF, and SDF-1alpha also showed significant 
elevation in plasma levels in DCM patients with advanced HF (NYHA III-IV) in 
comparison to control group. However, none of these investigated cytokines were able to 
show any prognostic potency in predicting mortality or necessity for heart transplantation in 
both CD patients and idiopathic DCM patients. 
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4.4.1. Role of hepatocyte growth factor as a serum biomarker in heart failure 
HGF was found to be significantly increased in plasma of patients with advanced HF 
(NYHA III-IV) in both CD and idiopathic DCM groups, but not in patients with HF of mild 
to moderate severity (NYHA I-II). However, HGF concentration in HF patients was lower 
than the values previously reported (Lamblin N et al., 2005; Rychli K et al., 2011). One 
reason for this difference in values could be the different methods used for cytokine 
measurement. In this study, Bio-Plex ProTM Assays system (Bio-Rad) was used, while in the 
previous two studies, traditional ELISA kit for HGF was used. However, the most probable 
reason could be the different composition of recruited patients and the treatment they 
received. It has been confirmed through various clinical trials that HGF concentration is 
positively correlated with age and clinical severity (Lamblin N et al., 2005; Rychli K et al., 
2011). In one of the trials (Rychli K et al., 2011), the median age of recruited patients is 
even 75 years and only advanced HF patients were included. On the other hand, the average 
age of HF patients in present study is only 49 years and patients from NYHA classes I-IV 
were included. 
Plasma HGF concentration may also have been influenced by the difference in treatment 
received by HF patients. In a previous study, only hospitalized HF patients with clinical 
signs and symptoms of cardiac decompensation (NYHA III-IV) were included, and blood 
was collected on the morning of discharge before the intake of medication (Rychli K et al., 
2011). In another study, peripheral blood was collected for HGF measurement at the time of 
entry into the study (Lamblin N et al., 2005). However, in this present study, the heart 
function of all patients was compensated and they were treated with maximal tolerated 
doses of ACEIs, ARBs, and other drugs, for at least three months before the blood was 
obtained. Since the dose of ACEIs has been found to be inversely correlated with HGF 
concentration (Rychli K et al., 2011) and most of the patients in present study received 
ACEI therapy, this may also be one of the reasons why the HGF concentration measured 
was lower than previously described. 
HGF is a cytokine that has been shown to be a strong and independent predictor of mortality 
in patients with advanced HF. However, this association is only present in patients with 
ischemic HF and not in those with HF from non-ischemic causes like CD. This may suggest 
the presence of discrete pathogenic pathways regulating the course of disease (Rychli K et 
Discussion  59 
 
al., 2011). Serum HGF levels seem to be regulated mainly in ischemic conditions of the 
heart. This is supported by the finding that HGF is released into the circulation after 
myocardial infarction (Zhu Y et al., 2000). HGF, which was originally identified as a potent 
mitogen for hepatocytes, is now known to have mitogenic, anti-apoptotic, angiogenic, and 
anti-fibroblast effects in various cell types in the body (Matsumoto K and Nakamura T, 
1996). The endogenous HGF system of the body protects the heart via its anti-apoptotic 
effect on cardiomyocytes and attenuates the development of HF with increased angiogenesis 
and decreased fibrosis and apoptosis (Lamblin N et al., 2005). HGF is known to be a growth 
factor for vascular tissues, and it has the most potent mitogenic activity among various 
known growth factors (Nakamura Y et al., 1996). Therefore, an increase in serum HGF 
concentration after an episode of acute myocardial infarction may contribute to the 
formation of new collateral blood vessels around the ischemic area (Zhu Y et al., 2000). In 
this study, patients with coronary artery diseases were excluded. Therefore, there were no 
cases of HF from ischemic causes in present study. 
It is also interesting to note that echocardiographic parameters have a close correlation with 
plasma HGF concentration in CD patients but not in patients with idiopathic DCM, despite 
the fact that CD leads to typical DCM. LVEF, for instance, is negatively correlated with 
plasma HGF levels in CD patients (p= 0.0009), but there is no strong correlation with HGF 
concentration in DCM patients (p= 0.1041). It would be very interesting if DCM due to 
specific etiology may have an effect on the generation and metabolism of HGF, and 
subsequently on the concentration of circulating HGF. If this can be proven, it might change 
our general understanding of DCM, since it is generally believed that the phenotype of 
DCM itself and not the causes of the phenotype determine the regulation of biomarkers of 
interest (Wang Y et al., 2012). Therefore, further investigations with more patients per 
specific etiology are required in order to clarify these mechanisms. 
4.4.2. Macrophage migration inhibitory factor as an inflammatory biomarker 
in heart failure 
MIF is another example of such a cytokine that is regulated in HF cases due to specific 
etiologies. Plasma MIF concentration has been found to be increased in patients with 
congestive heart failure, and interestingly the increase was more significant in cases of 
coronary artery disease as compared to the increase in levels observed in cases of DCM. 
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MIF is a pro-inflammatory cytokine which may be involved in inflammatory processes 
related to HF due to ischemic processes (Liu Y et al., 2003). Inflammation may be more 
severe in ischemic myocardium as compared to in DCM. In present study, mean plasma 
MIF concentration in patients with advanced HF (NYHA III-IV) due to CD (324.5±64.53 
pg/mL) was higher than the mean MIF levels in advanced HF patients with idiopathic DCM 
(196.9±20.72 pg/mL). Here again, it might indicate that inflammatory processes involved in 
the pathogenesis and progression of CD may be more severe and pronounced than in 
idiopathic DCM (Rossi MA et al., 2003; Nunes VL et al., 2006). 
4.4.3. Regulation of stem cell growth factor beta in heart failure – potential as a 
biomarker 
There were some cytokines in this study whose role in HF from various causes remains 
unknown and undefined. SCGF beta, for instance, had never been reported in HF patients 
prior to present study. SCGF is a novel human growth factor for hematopoietic progenitor 
cells. Two isoforms (alpha and beta) have been identified in humans. SCGF beta is 78 
amino acids shorter than SCGF alpha (Hiraoka A et al., 1997; Mio H et al., 1998). Both 
isoforms are bioactive and expressed in a similar way. SCGF beta exhibits burst-promoting 
activity and granulocyte/macrophage colony-stimulating activity on erythroid and 
granulocyte/macrophage progenitor cells in combination with other cytokines. Its 
concentration in serum is also known to increase following stem cell transplantation in 
patients (Ito C et al., 2003). 
In present study, SCGF beta was found to be significantly increased in plasma of advanced 
HF patients (NYHA III-IV) caused by CD and idiopathic DCM, as compared CD patients 
without HF. However, despite this significant increase in advanced HF patients, plasma 
SCGF beta concentration had no significant correlation with echocardiographic parameters. 
Similarly, Kaplan-Meier curves failed to visualize any significant predictive power of 
plasma SCGF beta concentration for risk in lethality or the necessity for heart 
transplantation in both CD and DCM patients. 
In recent times, it has been recognized that the endogenous bone marrow-cardiac axis may 
also play an important role in myocardial repair and functional recovery of patients with 
congestive heart failure. Hematopoietic stem and progenitor cells, especially endothelial 
progenitor cells (EPC), have been identified to be not only potential biomarkers for cardiac 
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events but also as therapeutic targets. There is a progressive decrease of circulating EPC 
with increasing severity of HF (Maltais S et al., 2011). On the other hand, mesenchymal 
stem cells and subset of hematopoietic stem cells were increased significantly at specific 
stages of HF. A number of investigated cytokines as mentioned above were also increased 
in HF patients (Fortini C et al., 2011). Therefore, corresponding cytokines and/or growth 
factors are needed for proliferation, mobilization, homing, and local function of bone 
marrow-derived stem or progenitor cells under HF condition, in order to regulate and sustain 
these processes. 
Serum SCGF beta levels are known to be raised after stem cell transplantation (Ito C et al., 
2003). Mobilized bone marrow cells that move towards the failing heart may influence local 
inflammatory processes and promote cardiac regeneration. This process may require SCGF 
beta. However, nothing has been reported about its concentration in HF patients. This study 
is the first to demonstrate SCGF beta in HF patients. Although there was a significant 
elevation in circulating SCGF beta levels in advanced HF patients in both CD and DCM 
groups, it had no correlation with LVEF and thus cannot be used as a prognostic marker for 
mortality and heart transplantation. Further studies need to be done in order to clarify the 
mechanism governing the SCGF beta regulation in advanced HF patients and the function 
such elevation might have. 
4.4.4. Possible role of monokine induced by interferon gamma as a serum 
biomarker in Chagas’ disease 
MIG is another cytokine whose role in patients with HF is unknown. In this study, plasma 
MIG concentration was significantly elevated in CD patients with advanced HF (NYHA III-
IV) (2,329 pg/mL) as compared with control group (808.4 pg/mL) (p < 0.001). Furthermore, 
circulating levels of MIG in CD patients with HF were considerably higher than the levels 
obtained in DCM patients with HF, although no statistical difference was observed in this 
case. Mean MIG concentration in CD patients (NYHA I-II) was 1695 pg/mL, more than 
twice the mean MIG levels recorded in DCM patients (NYHA I-II) (832.8 pg/mL). 
Similarly, in advanced HF patients with CD (NYHA III-IV) (2,329 pg/mL), mean MIG 
concentration was considerably higher than in DCM patients with advanced HF (NYHA III-
IV) (1,307 pg/mL). Even the mean plasma MIG level in CD patients with mild to moderate 
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HF (NYHA I-II) (1695 pg/mL) was recorded to be more than twice the mean MIG 
concentration observed in control subjects (808.4 pg/mL). 
Although circulating MIG concentration in CD patients with HF had no significant 
correlation with echocardiographic parameters like LVEF, significant correlation of plasma 
MIG levels with LVEF was found in DCM patients (p= 0.033). Correlation of LVEF in both 
CD and DCM groups was negative (MIG concentration increased with decrease in ejection 
fraction). On the other hand, Kaplan-Meier curves were unable to show any significant 
predictive power of MIG for risk in mortality or necessity for heart transplantation in both 
CD and DCM patients. 
MIG is a chemokine, which acts as a signaling molecule, regulating the movement of 
immune cells, directing them to sites of tissue injury and inflammation and modulating their 
states of activation and effecter cell function (Soloski MJ et al., 2014). MIG has been found 
to increase experimentally in mice with HF, although it is etiology dependent (Vistnes M et 
al., 2010). MIG has also been studied in experimental mice models infected with T.cruzi. It 
has been shown in these studies that MIG and other interferon gamma-inducible factors 
such as VCAM-1 (vascular cell adhesion molecule-1), and chemokines like RANTES 
(regulated upon activation, normal T-cell expressed and secreted) and MIP-1alpha are 
elevated in the myocardium of infected animals. The increased expression of chemokines 
like MIG in the myocardium may contribute to the heavy recruitment of activated T cells, 
and thus subsequently to the establishment and maintenance of T.cruzi induced myocarditis 
(dos Santos PV et al., 2001). 
The expression of gamma interferon-induced chemokines such as MIG and RANTES are 
increased in the inflamed myocardium during acute phase of infection and persist during the 
chronic phase as well. MIG is known to be involved in the selective recruitment of T helper 
1 (Th1) cells (Sallusto F et al., 1998). As discussed earlier, there is a strong Th1-immune 
response in acute phase of T.cruzi infection with presence of both CD4 and CD8, and 
characterized by the production of cytokines like gamma interferon, TNF alpha and IL-12 
which are important in the control of parasitic infection (Abrahamsohn IA and Coffman RL, 
1996). These cytokines cause the activation of trypanocidal activity of macrophages through 
NO-dependent mechanism (Chandra M et al., 2002; Gutierrez FR et al., 2009). 
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However, MIG and other cytokines mentioned above also persist during chronic phase of 
T.cruzi infection, and could play a damaging and harmful role in cardiomyopathy due to 
CD. NO may directly control the contractile properties of muscle cells and contribute to 
decreased cardiac function and myocardial damage. This could further enhance and worsen 
the chemokine-induced inflammation and tissue damage (Machado FS et al., 2000). 
This study was the first to demonstrate circulating MIG concentration in CD and idiopathic 
DCM patients with HF. Plasma MIG levels were found to be significantly raised in CD 
patients with advanced HF (NHA III-IV) compared to control subjects. Even when 
compared to DCM patients with HF (NYHA I-IV), MIG concentration in CD patients with 
HF (NYHA I-IV) was notably higher. As stated earlier, inflammation in CD is more severe 
and intense in comparison to that in idiopathic DCM. Furthermore, mononuclear cell 
infiltrate together with large areas of confluent fibrosis are seen throughout the myocardium 
in CD but not in idiopathic DCM (Rossi MA et al., 2003; Nunes VL et al., 2006). MIG 
might be one of the cytokines involved in the inflammatory reactions seen here in patients 
with cardiomyopathy due to CD and as already shown in experimental studies in animals 
(Sallusto F et al., 1998; dos Santo PV et al., 2001). In present study, although MIG failed to 
show any prognostic potency in CD and idiopathic DCM patients, the significant increase in 
MIG levels as seen in advanced HF patients with CD encourages the need for further studies 
to be done in order to investigate and explore the possible use of circulating MIG as a 
diagnostic and/or prognostic marker in CD. 
4.5. Multivariate analysis – use in diagnosis and prognosis of Chagas’ 
disease 
Multivariate analysis was used in this study in order to investigate whether two or more 
cytokines together could show any efficacy in diagnosing and prognosticating patients with 
CD. Most of the cytokines investigated in present study were regulated in the same manner. 
Cytokines such as MIF, SCGF beta, HGF, CTACK, and MIG only showed significant 
elevation in plasma levels in CD patients with advanced HF (NYHA III-IV). There were no 
significant changes in concentrations of cytokines in asymptomatic CD group or in CD 
patients with mild to moderate HF (NYHA I-II). In DCM group as well, plasma 
concentrations of SCGF beta and HGF were increased markedly only in patients with 
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advanced HF (NYHA III-IV). Therefore, multivariate analysis was unable to find any 
combination of two or more cytokines that could help in discriminating CD from idiopathic 
DCM. 
However, multivariate analysis did show some efficacy in prognosticating patients with CD 
and patients with DCM due to idiopathic causes. In case of CD group, it identified two 
cytokines by imputing, HGF and IL-12p40, which were able to separate 81.9% of survivors 
from the deceased (sensitivity/specificity of 92.9%/50.0%). Likewise in DCM group, SDF-
1alpha, SCF, and MIG were selected as best parameters through imputing, and were able to 
separate 77.1% of survivors from the deceased (sensitivity/specificity of 76.5%/77.4%). 
Although, multivariate analysis was unable to find a group of cytokines that could together 
discriminate CD from DCM due to idiopathic causes, it was, however, able to find a number 
of cytokines that prognosticated a large number of CD patients and idiopathic DCM 
patients. In future, further studies need to be done in order to identify cytokines that are 
regulated differently from one another and could possibly have greater efficacy together in 
diagnosing and prognosticating patients with CD and DCM. 
4.6. Possible role of other cytokines in prognosis of Chagas’ disease 
There is also a possibility that many other cytokines apart from the ones that we already 
investigated are regulated in CD and could potentially be used as prognostic markers in the 
future. Owing to the intensity and severity of inflammation in CD, it is possible that various 
other cytokines may be involved in the process. The immunological imbalance between pro- 
and anti-inflammatory cytokines is largely responsible for the myocardial damage seen in 
CD (Guedes PM et al., 2012). Pro-inflammatory cytokines such as interferon gamma, TNF 
alpha, and IL-6 are already known to be elevated in serum of CD patients (Mocelin AO et 
al., 2005; Marin-Neto JA et al., 2007), while the levels of anti-inflammatory cytokines, IL-
10 and IL-17, are reduced with increasing severity of HF in CD patients. This decreased 
production of the cytokines IL-10 and IL-17 together with raised levels of TNF alpha and 
interferon gamma is correlated with severity of CD (Guedes PM et al., 2012). Also, 
cytokines that promote fibrosis and extracellular matrix remodeling might be regulated in 
CD as cardiomyopathy due to CD is characterized by diffuse and widespread fibrosis within 
the myocardium (Rossi MA et al., 2003; Nunes VL et al., 2006). Therefore, further studies 
Discussion  65 
 
are required to identify other pro- and anti-inflammatory cytokines and those that induce 
fibrosis and extracellular matrix remodeling. 
4.7. Conclusion 
As mentioned above, HF is characterized by the activation of various inflammatory 
processes that result in increased levels of inflammatory markers such as IL-6 and CRP 
(Anker SD and von Haehling S, 2004). Cytokines levels are increased in patients with HF 
(Torre-Amione G et al., 1996), and are associated with the development of ventricular 
remodeling and progression of HF (Kelly RA and Smith TW, 1997; Li YY et al., 2000). 
Likewise, inflammation mediated by cytokines plays an important role in pathogenesis and 
progression of CD. However, inflammation in CD is much more severe and has an early, 
rapid onset as compared to in idiopathic DCM. Inflammatory infiltrate is present throughout 
the myocardium and there is widespread, diffuse fibrosis (Rossi M et al., 2003; Nunes VL et 
al., 2006). This widespread myocardial inflammation can lead to a more severe ventricular 
remodeling process, causing a rapid and severe onset HF, and ultimately death. The more 
intense inflammatory activation might be responsible for the poorer prognosis seen in CD 
when compared to DCM due to idiopathic causes. 
Owing to the increased severity of HF in CD, inflammatory pathways and biomarkers are 
regulated differently compared to in idiopathic DCM (Mocelin AO et al., 2005). By further 
identifying such serum inflammatory cytokines, we might be able to use them in future as 
tools for early prediction and prognosis of CD. In present study, twenty-one different 
cytokines were investigated in patients with CD and idiopathic DCM. Although, a number 
of cytokines such as HGF, MIG, and SCGF beta were found to be significantly elevated in 
serum of CD patients with advanced HF, none of them showed any potent predictive power 
for risk in lethality or necessity for heart transplantation. Perhaps some of the cytokines that 
were studied are only regulated in patients with HF due to specific etiologies. HGF, for 
example, is known to be a strong and independent predictor of mortality in patients with 
advanced HF. However, this association is only seen in patients with ischemic HF and not in 
those with HF from non-ischemic causes like CD (Rychli K et al., 2011). It is also possible 
that various other cytokines apart from the ones that were investigated here are involved in 
causing severe inflammation and widespread fibrosis seen in CD (Guedes PM et al., 2012). 
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Studies in future should focus more on identifying cytokines that are involved in chronic 
myocardial and systemic inflammatory activation seen in patients with CD. 
Although multivariate analysis was unable to discriminate patients with CD from patients 
with idiopathic DCM, it did find some cytokines that were together able to separate a large 
percentage of survivors from the deceased in both CD and DCM groups. However, most of 
the cytokines in this study were regulated in the same manner, and further studies should be 
encouraged in the future to identify cytokines that are regulated differently from one 
another, and could therefore have greater diagnostic and prognostic potency in CD and 
DCM. 
Considering that HF due to CD is associated with poor prognosis and survival (Pereira 
Nunes Mdo C et al., 2010; Barbosa AP et al., 2011), there is a need to identify serum 
biomarkers which could help in predicting the risk of developing DCM in chronically 
infected, asymptomatic patients. This would help in ensuring that the necessary treatment is 
provided in time to such patients in order to prevent the onset and progression of HF and 
thus prevent death. Such biomarkers would also help in prognosis and risk stratification of 
patients with CD, and in identifying patients who will benefit from heart transplantation. 
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5. Summary 
Chagas’ disease (CD), caused by the hemoflagellate protozoan, Trypanosoma cruzi, is endemic 
in most countries of South and Central America, where nearly 10 million people are infected 
with the parasite and another 25 million are at risk of infection. Cardiac involvement is the 
most frequent and serious manifestation of chronic CD, and typically leads to abnormalities 
of conduction system, heart failure (HF), thromboembolism, and sudden death. HF is often a 
late manifestation of chronic CD and is associated with higher mortality than is HF from 
other causes. Early identification of patients with CD, therefore, would be desirable as early 
intervention may help improve prognosis. Inflammatory biomarkers can play a vital role in 
early diagnosis, as inflammation mediated by cytokines plays an important role in 
pathogenesis and progression of CD, and may be present even in the absence of HF. 
Keeping in view the inflammatory nature of CD, this study investigated the possible role of 
21 different inflammatory cytokines as biomarkers for prediction and prognosis of CD. The 
plasma concentration of each of these cytokines was measured in a group of patients with 
CD, and then compared with those measured in patients with dilated cardiomyopathy 
(DCM) from idiopathic causes, and with control subjects. This study was the first to 
demonstrate cytokines such as monokine induced by interferon gamma (MIG) and stem cell 
growth factor beta (SCGF beta) in CD and idiopathic DCM patients with HF. Although 
plasma levels of cytokines like SCGF beta, hepatocyte growth factor (HGF), cutaneous T-
cell attracting chemokine (CTACK), and MIG were significantly increased in CD patients 
with advanced HF, they were unable to show any predictive or prognostic potency in CD. 
Multivariate analysis was able to prognosticate a large proportion of CD and DCM patients, 
but it could not discriminate CD from idiopathic DCM. It is possible that some of the 
cytokines that were investigated here are only regulated in HF due to specific etiologies 
such as ischemic HF. Also, cytokines other than the ones that were investigated may play a 
major role in causing severe inflammation and fibrosis seen in CD. 
Studies in future should focus on identifying more serum inflammatory biomarkers that 
could be used as tools for early prediction and prognosis of CD. As CD is associated with 
poor prognosis, identifying patients at an early stage of the disease may help in providing 
effective treatment and prevent the development of HF and thus early death. 
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6. Zusammenfassung 
Die Chagas-Krankheit (CD) ist eine von Trypanosoma cruzi verursachte 
Protozoeninfektion, die endemisch in den meisten Ländern Süd-und Mittelamerikas auftritt 
und 10 Millionen Menschen betrifft sowie weitere 25 Millionen Menschen gefährdet. Ein 
Herzphänotypist ist die häufigste und schwerste Manifestation der chronischen CD und 
führt meistens zu Störungen des Reizleitungssystems, zu Herzinsuffizienz (HF), 
Thromboembolien und plötzlichem Tod. Die HF ist oft eine späte Folge der CD und ist mit 
einer höheren Sterblichkeit verbunden als eine durch andere Ursachen hervorgerufene HF. 
Die Früherkennung der CD in Patienten wäre daher wünschenswert, da frühe Intervention 
zur Prognoseverbesserung führen kann. Entzündliche Biomarker können eine entscheidende 
Rolle bei der frühen Diagnose spielen, da die von Zytokinen vermittelte Entzündung eine 
wichtige Funktion in der Pathogenese und Progression von CD spielt und auch in 
Abwesenheit von einer HF vorhanden sein kann. 
Unter Berücksichtigung der entzündlichen Eigenschaften der CD ist in der vorliegenden 
Arbeit, die mögliche Rolle von 21 verschiedenen inflammatorischen Zytokinen als 
Biomarker für die Diagnose und Prognose der CD untersucht worden. Die 
Plasmakonzentration jedes dieser Zytokine wurde in einer Gruppe von Patienten mit CD 
gemessen und anschließend mit Werten von Patienten mit dilatativerKardiomyopathie 
(DCM) aus idiopathischen Gründen sowie mit den Werten von Kontrollpersonen 
verglichen. Die Studie zeigte zum ersten Mal Zytokine wie ‚monokine induced by interferon 
gamma‘ (MIG) und Stammzellwachstumsfaktor beta (SCGF Beta) in CD- und 
idiopathischen DCM-Patienten im Zusammenhang mit HF. Obwohl die Plasmaspiegel von 
Zytokinen wie SCGF beta, Hepatozyten-Wachstumsfaktor (HGF), kutanem T-Zell-
anziehendem Chemokin (CTACK) und MIG in CD-Patienten mit fortgeschrittener HF 
deutlich erhöht waren, konnte ihre diagnostische oder prädiktive Potenz in der CD nicht 
nachgewiesen werden. Die Multivariate Analyse konnte nicht zwischen CD-Patienten und 
idiopathischen DCM-Patienten unterscheiden, obwohl der klinische Verlauf für einen 
großen Anteil der CD- und DCM-Patienten richtig prognostiziert werden konnte. Es ist 
möglich, dass einige der hier untersuchten Zytokine nur in spezifischen Ätiologien der HF, 
wie z.B. der Ischämischen HF, reguliert werden. Außerdem können Zytokine, die von uns 
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nicht untersucht worden sind ebenfalls eine Rolle bei der Entstehung von schweren 
Entzündungen und Fibrose spielen, die bei CD beobachtet werden. 
Deshalb besteht die Notwendigkeit, dass sich weitere Studien mit der Identifizierung 
entzündlicher Serum-Biomarker, als Hilfsmittel für die frühe Diagnose und Prognose von 
CD, befassen. Da die chronische Chagas-Kardiomyopathie mit einer schlechten Prognose 
einhergeht, kann die Früherkennung der Krankheit die Einleitung einer wirksamen 
Behandlung ermöglichen und die Entwicklung einer HF und somit eines frühen Todes 
verhindern.
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7. List of abbreviations 
ACE2 Angiotensin converting enzyme2 
ACEI Angiotensin converting enzyme inhibitor 
AIDS Acquired immunodeficiency syndrome 
Apo A1 Apolipoprotein A1 
ARB Angiotensin receptor blocker 
Beta NGF Beta nerve growth factor 
BNP Brain natriuretic peptide 
CD Chagas’ disease 
CRP C-reactive protein 
CTACK Cutaneous T-cell attracting chemokine 
DALY Disabiltiy-adjusted life year 
DBP Diastolic blood pressure 
DCM Dilated cardiomyopathy 
ECG Electrocardiogram  
EDTA Ethylenediamine tetra-acetic acid 
ELISA Enzyme-linked immunosorbent assay 
EPC Endothelial progenitor cell 
FGF Fibroblast growth factor 
GRO alpha Growth related oncogene alpha 
HF Heart failure 
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HGF Hepatocyte growth factor 
HIV Human immunodeficiency virus 
HR Heart rate 
IFA Indirect immunofluorescence assay 
IFN-alpha2 Interferon-alpha2 
IgG Immunoglobulin G 
IL Interleukin 
IL-2R alpha Interleukin-2 receptor alpha 
LIF Leukemia inhibitory factor 
LV Left ventricular 
LVDD Left ventricular diastolic diameter 
LVEDV Left ventricular end-diastolic volume  
LVEF Left ventricular ejection fraction 
LVESV Left ventricular end-systolic volume 
LVSD Left ventricular systolic diameter 
MCP-3 Monocyte chemo-attractant protein-3 
M-CSF Macrophage-colony stimulating factor 
MIF Macrophage migration inhibitory factor 
MIG Monokine induced by interferon gamma 
MIP-1alpha Macrophage inflammatory protein-1alpha 
NO Nitric oxide 
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NYHA New York heart association 
P p-value, probability 
PCR Polymerase chain reaction 
r Pearson’s correlation coefficient 
RANTES Regulated upon activation, normal T-cell expressed and secreted 
ROC Receiver operating characteristic 
SBP Systolic blood pressure 
SCF Stem cell factor 
SCGF beta Stem cell growth factor beta 
SDF-1alpha Stromal derived factor-1alpha 
SEM Standard error of mean 
TGF Transforming growth factor 
TNF Tumour necrosis factor 
TRAIL TNF-related apoptosis inducing ligand 
VCAM-1 Vascular cell adhesion molecule-1 
VEGF Vascular endothelial growth factor 
vs. Versus  
WHO World Health Organization 
 
Orders of magnitude: 
µ micro (10-6) 
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m milli (10-3) 
p pico (10-12) 
Units of measurements: 
% percent 
°C degrees of Celsius 
g gram 
L liter 
m meter 
mmHg millimeter mercury 
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